{"content":"<li class=\"n-box-item date-title\" data-end=\"1370318399\" data-start=\"1370232000\" data-txt=\"Friday, December 20, 2019\">Monday, June  3, 2013</li><li class=\"n-box-item sa-box-item\" data-id=\"1061761\" data-ts=\"1370302681\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLCA\" target=\"_blank\">SLCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061761\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Silica (NYSE:SLCA) says a selling stockholder, Golden Gate Capital affiliate GGC USS...</a></h4><p>U.S. Silica (NYSE:<a href=\"https://seekingalpha.com/symbol/SLCA\" title=\"U.S. Silica\">SLCA</a>) says a selling stockholder, Golden Gate Capital affiliate GGC USS Holdings, intends to sell 10M shares in a secondary offering with an option for an additional 1.5M. <a href=\"https://seekingalpha.com/symbol/SLCA\" title=\"U.S. Silica\">SLCA</a> won't be selling any shares in the offering and will not receive any of the proceeds. Shares <font color=\"red\">-4%</font> AH.</p><div class=\"tiny-share-widget\" data-id=\"1061761\" data-linked=\"U.S. Silica (NYSE:SLCA) says a selling stockholder, Golden Gate Capital affiliate GGC USS...\" data-tweet=\"$SLCA - U.S. Silica (NYSE:SLCA) says a selling stockholder, Golden Gate Capital affiliate GGC USS Holdings, intends to sell 10M shares in a secondary offering with an option for an additional 1.5M. SLCA won&#39;t be selling any shares in the offering and wi... https://seekingalpha.com/news/1061761?source=tweet\" data-url=\"https://seekingalpha.com/news/1061761\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061711\" data-ts=\"1370297024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061711\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Himax (NASDAQ:HIMX) -2.8% AH to $6.93 after filing a fresh F-3 related to the company and top...</a></h4><p>Himax (NASDAQ:<a href=\"https://seekingalpha.com/symbol/HIMX\" title=\"Himax Technologies, Inc.\">HIMX</a>) <font color=\"red\">-2.8%</font> AH to $6.93 after <a target=\"_blank\" href=\"http://www.sec.gov/Archives/edgar/data/1342338/000104746913006700/a2215326zf-3.htm#da13301_use_of_proceeds\">filing a fresh F-3</a> related to the company and top customer/shareholder Innolux's plans to sell 50.9M ADS units, or 101.7M ordinary shares (<a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/984901\">first announced</a> on April 30). Innolux proposes to potentially sell its entire 15% stake, which translates into 50.8M ordinary shares. The proposed maximum offering price for Himax and Innolux's stock offerings is set at $3.50 per ordinary share, or $7 per ADS.</p><div class=\"tiny-share-widget\" data-id=\"1061711\" data-linked=\"Himax (NASDAQ:HIMX) -2.8% AH to $6.93 after filing a fresh F-3 related to the company and top...\" data-tweet=\"$HIMX - Himax (NASDAQ:HIMX) -2.8% AH to $6.93 after filing a fresh F-3 related to the company and top customer/shareholder Innolux&#39;s plans to sell 50.9M ADS units, or 101.7M ordinary shares (first announced on April 30). Innolux proposes to potentially ... https://seekingalpha.com/news/1061711?source=tweet\" data-url=\"https://seekingalpha.com/news/1061711\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061701\" data-ts=\"1370296966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/POR\" target=\"_blank\">POR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061701\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portland General Electric (NYSE:POR) -3.1% AH after announcing the suspension of its proposed...</a></h4><p>Portland General Electric (NYSE:<a href=\"https://seekingalpha.com/symbol/POR\" title=\"Portland General Electric Company\">POR</a>) <font color=\"red\">-3.1%</font> AH after announcing the suspension of its proposed Cascade Crossing transmission project, the completion of bids for construction of a new gas-fired power plant and a new wind farm, and a reduction of its FY 2013 EPS guidance to $1.35-$1.50 from $1.85-$2.00 vs. $1.92 consensus estimate.</p><div class=\"tiny-share-widget\" data-id=\"1061701\" data-linked=\"Portland General Electric (NYSE:POR) -3.1% AH after announcing the suspension of its proposed...\" data-tweet=\"$POR - Portland General Electric (NYSE:POR) -3.1% AH after announcing the suspension of its proposed Cascade Crossing transmission project, the completion of bids for construction of a new gas-fired power plant and a new wind farm, and a reduction of it... https://seekingalpha.com/news/1061701?source=tweet\" data-url=\"https://seekingalpha.com/news/1061701\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061631\" data-ts=\"1370295919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DS\" target=\"_blank\">DS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061631\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\"> Newcastle Investment (NCT) declares $0.17/share quarterly dividend. Forward yield 13.3% For...</a></h4><b> Newcastle Investment (NCT)</b> declares $0.17/share quarterly dividend. Forward yield 13.3% For shareholders of record June 13.Payable July 31.Ex-div date June 11. Shares  <font color=\"green\">+3.7%</font> AH. (PR)<div class=\"tiny-share-widget\" data-id=\"1061631\" data-linked=\" Newcastle Investment (NCT) declares $0.17/share quarterly dividend. Forward yield 13.3% For...\" data-tweet=\"$DS - Newcastle Investment (NCT) declares $0.17/share quarterly dividend. Forward yield 13.3% For shareholders of record June 13.Payable July 31.Ex-div date June 11. Shares +3.7% AH. (PR) https://seekingalpha.com/news/1061631?source=tweet\" data-url=\"https://seekingalpha.com/news/1061631\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061611\" data-ts=\"1370295233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCHP\" target=\"_blank\">MCHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061611\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microchip (NASDAQ:MCHP) +4.5% after raising its FQ1 (ends June 30) guidance. The microcontroller...</a></h4><p>Microchip (NASDAQ:<a href=\"https://seekingalpha.com/symbol/MCHP\" title=\"Microchip Technology Incorporated\">MCHP</a>) <font color=\"green\">+4.5%</font> after raising its FQ1 (ends June 30) guidance. The microcontroller vendor now expects 4%-7% Q/Q sales growth and EPS of $0.52-$0.56; that's better than prior guidance of 2%-6% growth and EPS of $0.50-$0.54, and largely above a consensus of $447.7M and $0.52. Microchip, <a href=\"https://seekingalpha.com/currents/post/85984\" target=\"_blank\">often seen as a bellwether</a> for chip stocks (<a href=\"https://seekingalpha.com/symbol/SOXX\" title=\"iShares PHLX SOX Semiconductor Sector Index ETF\">SOXX</a>, <a href=\"https://seekingalpha.com/symbol/SMH\" title=\"VanEck Vectors Semiconductor ETF\">SMH</a>), says it has \"continued to see a very strong bookings and business environment,\" has \"received excellent visibility\" from customers, and is returning employees to work faster than expected to keep inventories from falling too low. Microchip's guidance hike comes after <a href=\"http://blogs.barrons.com/techtraderdaily/2013/06/03/this-morning-intel-spreads-its-wings-msft-ponders-restructuring-p-tanks/\" target=\"_blank\">the SIA estimated</a> chip sales fell 10% M/M in March, better than a historical drop of 15.3%.</p><div class=\"tiny-share-widget\" data-id=\"1061611\" data-linked=\"Microchip (NASDAQ:MCHP) +4.5% after raising its FQ1 (ends June 30) guidance. The microcontroller...\" data-tweet=\"$MCHP $MCHP $SOXX - Microchip (NASDAQ:MCHP) +4.5% after raising its FQ1 (ends June 30) guidance. The microcontroller vendor now expects 4%-7% Q/Q sales growth and EPS of $0.52-$0.56; that&#39;s better than prior guidance of 2%-6% growth and EPS of $0.50-$0.... https://seekingalpha.com/news/1061611?source=tweet\" data-url=\"https://seekingalpha.com/news/1061611\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061601\" data-ts=\"1370295133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIII\" target=\"_blank\">GIII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061601\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After-hours top gainers, as of 5:15 p.m.: GIII +7%. CHUY +5%. FTNT +4%. QLIK +4%. ACHN +4%....</a></h4><b>After-hours top gainers, as of 5:15 p.m.:</b> <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color=\"green\">+7%</font>. <a href='https://seekingalpha.com/symbol/CHUY' title='Chuy&#39;s Holdings'>CHUY</a> <font color=\"green\">+5%</font>. <a href='https://seekingalpha.com/symbol/FTNT' title='Fortinet, Inc.'>FTNT</a> <font color=\"green\">+4%</font>. <a href='https://seekingalpha.com/symbol/QLIK' title='Qlik Technologies Inc.'>QLIK</a> <font color=\"green\">+4%</font>. <a href='https://seekingalpha.com/symbol/ACHN' title='Achillion Pharmaceuticals, Inc.'>ACHN</a> <font color=\"green\">+4%</font>. <br /><b>After-hours top losers:</b> <a href='https://seekingalpha.com/symbol/RECN' title='Resources Connection, Inc.'>RECN</a> <font color=\"red\">-7%</font>. <a href='https://seekingalpha.com/symbol/LGND' title='Ligand Pharmaceuticals Incorporated'>LGND</a> <font color=\"red\">-7%</font>. <a href='https://seekingalpha.com/symbol/MXWL' title='Maxwell Technologies, Inc.'>MXWL</a> <font color=\"red\">-6%</font>. <a href='https://seekingalpha.com/symbol/FSYS' title='Fuel Systems Solutions, Inc.'>FSYS</a> <font color=\"red\">-5%</font>. <a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a> <font color=\"red\">-5%</font>.<div class=\"tiny-share-widget\" data-id=\"1061601\" data-linked=\"After-hours top gainers, as of 5:15 p.m.: GIII +7%. CHUY +5%. FTNT +4%. QLIK +4%. ACHN +4%....\" data-tweet=\"$GIII $GIII $CHUY - After-hours top gainers, as of 5:15 p.m.: GIII +7%. CHUY +5%. FTNT +4%. QLIK +4%. ACHN +4%. After-hours top losers: RECN -7%. LGND -7%. MXWL -6%. FSYS -5%. ARRY -5%. https://seekingalpha.com/news/1061601?source=tweet\" data-url=\"https://seekingalpha.com/news/1061601\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061571\" data-ts=\"1370294455\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GM\" target=\"_blank\">GM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061571\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GM is finally returning to the S&amp;amp;P 500: the auto giant will replace Heinz (HNZ), which is...</a></h4><a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a> is finally <a href=\"https://twitter.com/BloombergNews/status/341664939099947008\" target=\"_blank\">returning to the S&amp;P 500</a>: the auto giant will replace Heinz (HNZ), which is getting acquired by Berkshire Hathaway and 3G Capital. <a href='https://seekingalpha.com/symbol/GM' title='General Motors Company'>GM</a> <font color=\"green\">+4.7%</font> AH.<div class=\"tiny-share-widget\" data-id=\"1061571\" data-linked=\"GM is finally returning to the S&amp;amp;P 500: the auto giant will replace Heinz (HNZ), which is...\" data-tweet=\"$GM $GM $KHC - GM is finally returning to the S&amp;P 500: the auto giant will replace Heinz (HNZ), which is getting acquired by Berkshire Hathaway and 3G Capital. GM +4.7% AH. https://seekingalpha.com/news/1061571?source=tweet\" data-url=\"https://seekingalpha.com/news/1061571\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061541\" data-ts=\"1370294197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRNT\" target=\"_blank\">VRNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061541\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verint Systems (NASDAQ:VRNT): Q1 EPS of $0.44 misses by $0.08. Revenue of $204.8M beats by...</a></h4><b>Verint Systems (NASDAQ:<a href=\"https://seekingalpha.com/symbol/VRNT\" title=\"Verint Systems Inc.\">VRNT</a>):</b> Q1 EPS of $0.44 <font color=\"red\">misses by $0.08</font>. Revenue of $204.8M <font color=\"green\">beats by $1.46M</font>. Shares  <font color=\"red\">-3.1%</font> AH. (PR)<div class=\"tiny-share-widget\" data-id=\"1061541\" data-linked=\"Verint Systems (NASDAQ:VRNT): Q1 EPS of $0.44 misses by $0.08. Revenue of $204.8M beats by...\" data-tweet=\"$VRNT - Verint Systems (NASDAQ:VRNT): Q1 EPS of $0.44 misses by $0.08. Revenue of $204.8M beats by $1.46M. Shares -3.1% AH. (PR) https://seekingalpha.com/news/1061541?source=tweet\" data-url=\"https://seekingalpha.com/news/1061541\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061521\" data-ts=\"1370294050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABM\" target=\"_blank\">ABM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061521\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ABM Industries (NYSE:ABM): FQ2 EPS of $0.36 beats by $0.03. Revenue of $1.17B misses by $0.01B....</a></h4><b>ABM Industries (NYSE:<a href=\"https://seekingalpha.com/symbol/ABM\" title=\"ABM Industries Incorporated\">ABM</a>):</b> FQ2 EPS of $0.36 <font color=\"green\">beats by $0.03</font>. Revenue of $1.17B <font color=\"red\">misses by $0.01B</font>. Shares  <font color=\"green\">+3.3%</font> AH. (PR)<div class=\"tiny-share-widget\" data-id=\"1061521\" data-linked=\"ABM Industries (NYSE:ABM): FQ2 EPS of $0.36 beats by $0.03. Revenue of $1.17B misses by $0.01B....\" data-tweet=\"$ABM - ABM Industries (NYSE:ABM): FQ2 EPS of $0.36 beats by $0.03. Revenue of $1.17B misses by $0.01B. Shares +3.3% AH. (PR) https://seekingalpha.com/news/1061521?source=tweet\" data-url=\"https://seekingalpha.com/news/1061521\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061551\" data-ts=\"1370293918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CP\" target=\"_blank\">CP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061551\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Pacific (NYSE:CP) -2.9% AH on news Pershing Square Capital plans to sell up to 7M of...</a></h4><p>Canadian Pacific (NYSE:<a href=\"https://seekingalpha.com/symbol/CP\" title=\"Canadian Pacific Railway Limited\">CP</a>) <font color=\"red\">-2.9%</font> AH on news Pershing Square Capital <a href=\"http://business.financialpost.com/2013/06/03/pershing-square-says-it-plans-to-sell-roughly-30-of-stake-in-cp-rail/\" target=\"_blank\">plans to sell up to 7M of its 24M shares</a> in the railroad over the next six months to a year. Share price gains have pushed CP to comprise 26% of the hedge fund's holdings, Bill Ackman says in citing the reason for the pullback, but traders wonder if the Icahn-induced short squeeze in Herbalife (NYSE:<a href=\"https://seekingalpha.com/symbol/HLF\" title=\"Herbalife Ltd.\">HLF</a>) is <a href=\"http://www.streetinsider.com/Hedge+Funds/Is+the+Herbalife+%28HLF%29+Squeeze+Forcing+Ackman+to+Sell+CP+%28CP%29+Prematurely%3F/8386398.html\" target=\"_blank\">forcing the sale</a>.</p><div class=\"tiny-share-widget\" data-id=\"1061551\" data-linked=\"Canadian Pacific (NYSE:CP) -2.9% AH on news Pershing Square Capital plans to sell up to 7M of...\" data-tweet=\"$CP $CP $HLF - Canadian Pacific (NYSE:CP) -2.9% AH on news Pershing Square Capital plans to sell up to 7M of its 24M shares in the railroad over the next six months to a year. Share price gains have pushed CP to comprise 26% of the hedge fund&#39;s holdings... https://seekingalpha.com/news/1061551?source=tweet\" data-url=\"https://seekingalpha.com/news/1061551\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061531\" data-ts=\"1370293810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIII\" target=\"_blank\">GIII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061531\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on G-III Apparel&#39;s (NASDAQ:GIII) Q1: Strength from &quot;a variety of businesses and the...</a></h4><p>More on G-III Apparel's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/GIII\" title=\"G-III Apparel Group, LTD.\">GIII</a>) <a href=\"https://seekingalpha.com/currents/post/1061491\" target=\"_blank\">Q1</a>: Strength from \"a variety of businesses and the inclusion of sales from Vilebrequin\" drive a 19% Y/Y increase in revenues. The company sees strong performance across product categories and retail operations turn in same-store sales growth in the double-digits. CEO Morris Goldfarb says \"positive feedback\" from retail customers gives him \"increased confidence in [the] full year outlook.\" FY14 EPS guidance is raised to $3.20-3.30 versus consensus of $3.20. Shares <font color=\"green\">+7.1%</font> AH. (PR)</p><div class=\"tiny-share-widget\" data-id=\"1061531\" data-linked=\"More on G-III Apparel&#39;s (NASDAQ:GIII) Q1: Strength from &quot;a variety of businesses and the...\" data-tweet=\"$GIII - More on G-III Apparel&#39;s (NASDAQ:GIII) Q1: Strength from &quot;a variety of businesses and the inclusion of sales from Vilebrequin&quot; drive a 19% Y/Y increase in revenues. The company sees strong performance across product categories and retail operatio... https://seekingalpha.com/news/1061531?source=tweet\" data-url=\"https://seekingalpha.com/news/1061531\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061481\" data-ts=\"1370293061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QLIK\" target=\"_blank\">QLIK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061481\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qlik (NASDAQ:QLIK) +4% AH after naming former Crane and Xerox Europe CFO Tim MacCarrick its new...</a></h4><p>Qlik (NASDAQ:<a href=\"https://seekingalpha.com/symbol/QLIK\" title=\"Qlik Technologies Inc.\">QLIK</a>) <font color=\"green\">+4%</font> AH after naming former Crane and Xerox Europe CFO Tim MacCarrick its new CFO, effective July 1. MacCarrick will replace Bill Sorenson, who <a href=\"https://seekingalpha.com/currents/post/829741\" target=\"_blank\">announced plans to resign</a> for \"personal reasons\" in February. Qlik is also naming former Cisco and AllScripts HR exec Diane Adams its new HR chief; she'll replace Paul Farmer, who has held the job for two years. (PR)</p><div class=\"tiny-share-widget\" data-id=\"1061481\" data-linked=\"Qlik (NASDAQ:QLIK) +4% AH after naming former Crane and Xerox Europe CFO Tim MacCarrick its new...\" data-tweet=\"$QLIK - Qlik (NASDAQ:QLIK) +4% AH after naming former Crane and Xerox Europe CFO Tim MacCarrick its new CFO, effective July 1. MacCarrick will replace Bill Sorenson, who announced plans to resign for &quot;personal reasons&quot; in February. Qlik is also naming f... https://seekingalpha.com/news/1061481?source=tweet\" data-url=\"https://seekingalpha.com/news/1061481\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061451\" data-ts=\"1370292059\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRY\" target=\"_blank\">ARRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061451\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Array BioPharma (NASDAQ:ARRY) announces a $100M offering of convertible senior notes due 2020,...</a></h4><p>Array BioPharma (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ARRY\" title=\"Array BioPharma Inc.\">ARRY</a>) announces a $100M offering of convertible senior notes due 2020, with a 30-day option to purchase up to an additional $15M. Goldman Sachs and JPMorgan Securities are acting as joint book-running managers. Shares <font color=\"red\">-4.5%</font> AH.</p><div class=\"tiny-share-widget\" data-id=\"1061451\" data-linked=\"Array BioPharma (NASDAQ:ARRY) announces a $100M offering of convertible senior notes due 2020,...\" data-tweet=\"$ARRY - Array BioPharma (NASDAQ:ARRY) announces a $100M offering of convertible senior notes due 2020, with a 30-day option to purchase up to an additional $15M. Goldman Sachs and JPMorgan Securities are acting as joint book-running managers. Shares -4.... https://seekingalpha.com/news/1061451?source=tweet\" data-url=\"https://seekingalpha.com/news/1061451\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061421\" data-ts=\"1370291791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BB\" target=\"_blank\">BB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061421\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BlackBerry (BBRY -2.4%) fell once more today. A possible trigger: Kantar Worldpanel estimated...</a></h4><p>BlackBerry (BBRY <font color=\"red\">-2.4%</font>) fell once more today. A possible trigger: <a href=\"http://thenextweb.com/insider/2013/06/03/kantar-android-took-52-of-us-smartphone-sales-in-april-but-ios-and-windows-phone-are-growing-faster/\" target=\"_blank\">Kantar Worldpanel estimated</a> BlackBerry accounted for just 0.7% of U.S. smartphone sales from February-April, in spite of AT&amp;T and Verizon's late-March <a href=\"https://seekingalpha.com/currents/post/905611\" target=\"_blank\">Z10 launches</a>. The number is down from the 5.3% estimated for a year ago, and also the 0.9% estimated for January-March. SA contributor <a href=\"https://seekingalpha.com/article/1476211-blackberry-10-demand-estimated-at-1-5-million-units-per-month\" target=\"_blank\">Elephant Analytics</a> argues Kantar tends to understate high-end phone sales.</p><div class=\"tiny-share-widget\" data-id=\"1061421\" data-linked=\"BlackBerry (BBRY -2.4%) fell once more today. A possible trigger: Kantar Worldpanel estimated...\" data-tweet=\"$BB - BlackBerry (BBRY -2.4%) fell once more today. A possible trigger: Kantar Worldpanel estimated BlackBerry accounted for just 0.7% of U.S. smartphone sales from February-April, in spite of AT&amp;T and Verizon&#39;s late-March Z10 launches. The number is do... https://seekingalpha.com/news/1061421?source=tweet\" data-url=\"https://seekingalpha.com/news/1061421\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061381\" data-ts=\"1370290834\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VMW\" target=\"_blank\">VMW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061381\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Though VMware&#39;s (VMW -2.4%) management has declared the cash flow guidance recently provided by...</a></h4><p>Though VMware's (<a href=\"https://seekingalpha.com/symbol/VMW\" title=\"VMware, Inc.\">VMW</a> <font color=\"red\">-2.4%</font>) management has declared the cash flow guidance <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/1056111\">recently provided</a> by parent EMC inaccurate (due to differences in accounting), subsequent talks with management \"imply that they are not entirely comfortable with Street numbers,\" says Nomura's <a target=\"_blank\" href=\"http://blogs.barrons.com/techtraderdaily/2013/06/03/vmware-awkward-situation-with-cash-flow-guidance-says-nomura/\">Rick Sherlund</a>, following up on his <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/1058031\">Friday note</a>. Management's remarks suggest op. cash flow growth will match op. income growth - Sherlund had been forecasting the former would grow 15%, and believes the consensus for the latter was 24%. He doesn't know whether the shortfall is due to \"high receivables or working capital,\" or demand issues, but thinks the lack of clarity makes for an \"awkward situation.\" Investors don't seem thrilled either.</p><div class=\"tiny-share-widget\" data-id=\"1061381\" data-linked=\"Though VMware&#39;s (VMW -2.4%) management has declared the cash flow guidance recently provided by...\" data-tweet=\"$VMW $VMW $DELL - Though VMware&#39;s (VMW -2.4%) management has declared the cash flow guidance recently provided by parent EMC inaccurate (due to differences in accounting), subsequent talks with management &quot;imply that they are not entirely comfortable wi... https://seekingalpha.com/news/1061381?source=tweet\" data-url=\"https://seekingalpha.com/news/1061381\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061291\" data-ts=\"1370289624\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061291\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">It&#39;s a rough day for Elon Musk&#39;s stocks. In addition to Tesla, SolarCity (SCTY -9.9%) has given...</a></h4><p>It's a rough day for Elon Musk's stocks. In addition to <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/1061211\">Tesla</a>, SolarCity (SCTY <font color=\"red\">-9.9%</font>) has given back some of this year's giant gains, <a target=\"_blank\" href=\"http://www.bloomberg.com/news/2013-06-03/solarcity-slumps-before-lockup-expires-on-82-of-shares.html\">possibly thanks to concerns</a> about its June 11 lockup expiration. Nearly 61.6M shares, or 82% of SolarCity's outstanding shares, become eligible for sale following the expiration. \"The floodgates are about to open,\" says Raymond James' Alex Morris. Musk owns 28% of SolarCity, or a little over a third of the shares affected by the expiration. (<a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/1033831\">previous</a>)</p><div class=\"tiny-share-widget\" data-id=\"1061291\" data-linked=\"It&#39;s a rough day for Elon Musk&#39;s stocks. In addition to Tesla, SolarCity (SCTY -9.9%) has given...\" data-tweet=\"$TSLA - It&#39;s a rough day for Elon Musk&#39;s stocks. In addition to Tesla, SolarCity (SCTY -9.9%) has given back some of this year&#39;s giant gains, possibly thanks to concerns about its June 11 lockup expiration. Nearly 61.6M shares, or 82% of SolarCity&#39;s out... https://seekingalpha.com/news/1061291?source=tweet\" data-url=\"https://seekingalpha.com/news/1061291\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061261\" data-ts=\"1370288963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061261\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs isn&#39;t buying into the lovefest on Merck&#39;s (MRK +3.7%) presentation today on its...</a></h4><p>Goldman Sachs isn't buying into the lovefest on Merck's (<a href=\"https://seekingalpha.com/symbol/MRK\" title=\"Merck &amp; Co Inc.\">MRK</a> <font color=\"green\">+3.7%</font>) presentation today on its <a target=\"_blank\" href=\"http://www.streetinsider.com/Analyst+Comments/Merck+%28MRK%29+Immuno-Oncology+Offering+Lacks+Combo%3B+Goldman+Maintains+Neutral/8386083.html\">oncology offerings</a>. Analyst Jami Rubin notes that Lambro is a strong single agent immuno-oncology drug but the company is missing out on \"combo potential,\" which are likely to take the majority share of the immuno-oncology market.</p><div class=\"tiny-share-widget\" data-id=\"1061261\" data-linked=\"Goldman Sachs isn&#39;t buying into the lovefest on Merck&#39;s (MRK +3.7%) presentation today on its...\" data-tweet=\"$MRK - Goldman Sachs isn&#39;t buying into the lovefest on Merck&#39;s (MRK +3.7%) presentation today on its oncology offerings. Analyst Jami Rubin notes that Lambro is a strong single agent immuno-oncology drug but the company is missing out on &quot;combo potentia... https://seekingalpha.com/news/1061261?source=tweet\" data-url=\"https://seekingalpha.com/news/1061261\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061221\" data-ts=\"1370288197\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZNGA\" target=\"_blank\">ZNGA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061221\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zynga (ZNGA -11.6%) resumes trading following the layoff of 18% of its workforce.</a></h4>Zynga (<a href='https://seekingalpha.com/symbol/ZNGA' title='Zynga'>ZNGA</a> <font color=\"red\">-11.6%</font>) resumes trading following the <a href=\"https://seekingalpha.com/currents/post/1061191\" target=\"_blank\">layoff of 18%</a> of its workforce.<div class=\"tiny-share-widget\" data-id=\"1061221\" data-linked=\"Zynga (ZNGA -11.6%) resumes trading following the layoff of 18% of its workforce.\" data-tweet=\"$ZNGA - Zynga (ZNGA -11.6%) resumes trading following the layoff of 18% of its workforce. https://seekingalpha.com/news/1061221?source=tweet\" data-url=\"https://seekingalpha.com/news/1061221\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061211\" data-ts=\"1370287884\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061211\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla Motors (TSLA -6.7%) slips as Autodata estimates the company may have sold 1,425 units of...</a></h4><p>Tesla Motors (<a href=\"https://seekingalpha.com/symbol/TSLA\" title=\"Tesla, Inc.\">TSLA</a> <font color=\"red\">-6.7%</font>) slips as Autodata estimates the <a href=\"http://www.streetinsider.com/Retail+Sales/Tesla+%28TSLA%29+Model+S+Sales+Said+to+be+1%2C425+Units+in+May/8385824.html\" target=\"_blank\">company may have sold</a> 1,425 units of its Model S sedan in May. Year-to-date Model S sales are estimated to be about 7,506 units. During Q1, the company produced 400 or more Model S vehicles a week, for a total of over 5,000.</p><div class=\"tiny-share-widget\" data-id=\"1061211\" data-linked=\"Tesla Motors (TSLA -6.7%) slips as Autodata estimates the company may have sold 1,425 units of...\" data-tweet=\"$TSLA - Tesla Motors (TSLA -6.7%) slips as Autodata estimates the company may have sold 1,425 units of its Model S sedan in May. Year-to-date Model S sales are estimated to be about 7,506 units. During Q1, the company produced 400 or more Model S vehicl... https://seekingalpha.com/news/1061211?source=tweet\" data-url=\"https://seekingalpha.com/news/1061211\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061201\" data-ts=\"1370287720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GG\" target=\"_blank\">GG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061201\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold mining stocks (NYSEARCA:GDX) could be reaching an inflection point, Barclays believes,...</a></h4><p>Gold mining stocks (NYSEARCA:<a href=\"https://seekingalpha.com/symbol/GDX\" title=\"VanEck Vectors Gold Miners ETF\">GDX</a>) could be <a target=\"_blank\" href=\"http://blogs.barrons.com/emergingmarketsdaily/2013/06/03/gold-miners-at-inflection-point-barclays-says\">reaching an inflection point</a>, Barclays believes, pointing to early signs of performance improvement through the many cost reduction programs begun this year, plus compelling valuations. Goldcorp (<a href=\"https://seekingalpha.com/symbol/GG\" title=\"Goldcorp Inc.\">GG</a> <font color=\"green\">+2.1%</font>) is the firm's top pick among North American miners because it has the best growth profile and expected operating and capital cost declines in 2014.</p><div class=\"tiny-share-widget\" data-id=\"1061201\" data-linked=\"Gold mining stocks (NYSEARCA:GDX) could be reaching an inflection point, Barclays believes,...\" data-tweet=\"$GG $GDX $GG - Gold mining stocks (NYSEARCA:GDX) could be reaching an inflection point, Barclays believes, pointing to early signs of performance improvement through the many cost reduction programs begun this year, plus compelling valuations. Goldcorp ... https://seekingalpha.com/news/1061201?source=tweet\" data-url=\"https://seekingalpha.com/news/1061201\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061151\" data-ts=\"1370286378\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSP\" target=\"_blank\">HSP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061151\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hospira (HSP +1.2%) says results from a post-marketing study of the company&#39;s European...</a></h4><p>Hospira (<a href=\"https://seekingalpha.com/symbol/HSP\" title=\"Hospira, Inc.\">HSP</a> <font color=\"green\">+1.2%</font>) says results from a post-marketing study of the company's European biosimilar epoetin, Retacrit, met its primary endpoint in the management of chemotherapy-induced anemia in adult patients with solid tumors, lymphomas and myelomas, regardless of chemotherapy cycle..</p><div class=\"tiny-share-widget\" data-id=\"1061151\" data-linked=\"Hospira (HSP +1.2%) says results from a post-marketing study of the company&#39;s European...\" data-tweet=\"$HSP - Hospira (HSP +1.2%) says results from a post-marketing study of the company&#39;s European biosimilar epoetin, Retacrit, met its primary endpoint in the management of chemotherapy-induced anemia in adult patients with solid tumors, lymphomas and myel... https://seekingalpha.com/news/1061151?source=tweet\" data-url=\"https://seekingalpha.com/news/1061151\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061091\" data-ts=\"1370285486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OC\" target=\"_blank\">OC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061091\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Owens Corning (OC -1.2%) says it&#39;s completed the acquisition of Thermafiber, a manufacturer of...</a></h4><p>Owens Corning (<a href=\"https://seekingalpha.com/symbol/OC\" title=\"Owens Corning\">OC</a> <font color=\"red\">-1.2%</font>) says it's completed the acquisition of Thermafiber, a manufacturer of mineral wool commercial and industrial insulation products. Financial terms of the deal were not disclosed.</p><div class=\"tiny-share-widget\" data-id=\"1061091\" data-linked=\"Owens Corning (OC -1.2%) says it&#39;s completed the acquisition of Thermafiber, a manufacturer of...\" data-tweet=\"$OC - Owens Corning (OC -1.2%) says it&#39;s completed the acquisition of Thermafiber, a manufacturer of mineral wool commercial and industrial insulation products. Financial terms of the deal were not disclosed. https://seekingalpha.com/news/1061091?source=tweet\" data-url=\"https://seekingalpha.com/news/1061091\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061071\" data-ts=\"1370285356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KAR\" target=\"_blank\">KAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061071\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KAR Auction Services (KAR -3.9%) slides after announcing a 15M share secondary. (PR)</a></h4><p>KAR Auction Services (<a href=\"https://seekingalpha.com/symbol/KAR\" title=\"KAR Auction Services\">KAR</a> <font color=\"red\">-3.9%</font>) slides after announcing a 15M share secondary. (PR)</p><div class=\"tiny-share-widget\" data-id=\"1061071\" data-linked=\"KAR Auction Services (KAR -3.9%) slides after announcing a 15M share secondary. (PR)\" data-tweet=\"$KAR - KAR Auction Services (KAR -3.9%) slides after announcing a 15M share secondary. (PR) https://seekingalpha.com/news/1061071?source=tweet\" data-url=\"https://seekingalpha.com/news/1061071\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061061\" data-ts=\"1370284937\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGYS\" target=\"_blank\">AGYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061061\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agilysys (AGYS +5.1%) jumps after saying it will sell its retail solutions group for $34.55M,...</a></h4><p>Agilysys (<a href=\"https://seekingalpha.com/symbol/AGYS\" title=\"Agilysys, Inc.\">AGYS</a> <font color=\"green\">+5.1%</font>) jumps after saying it will sell its retail solutions group for $34.55M, giving it cash of $110M post-sale. (PR)</p><div class=\"tiny-share-widget\" data-id=\"1061061\" data-linked=\"Agilysys (AGYS +5.1%) jumps after saying it will sell its retail solutions group for $34.55M,...\" data-tweet=\"$AGYS - Agilysys (AGYS +5.1%) jumps after saying it will sell its retail solutions group for $34.55M, giving it cash of $110M post-sale. (PR) https://seekingalpha.com/news/1061061?source=tweet\" data-url=\"https://seekingalpha.com/news/1061061\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1061041\" data-ts=\"1370284524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGL\" target=\"_blank\">MDGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1061041\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synta Pharmaceuticals (SNTA -34.1%) plummets as the market&#39;s interpretation of results from a...</a></h4><p>Synta Pharmaceuticals (SNTA <font color=\"red\">-34.1%</font>) plummets as the market's interpretation of results from a Phase 2b/3 trial of the Hsp90 inhibitor ganetespib is far less sanguine than the company's own take on the data. SNTA notes that \"the combination of ganetespib plus docetaxel improves overall, and progression-free-survival compared to docetaxel alone,\" but investors <a href=\"http://www.thestreet.com/story/11939068/1/syntas-lung-cancer-drug-struggles-to-remain-relevant.html\" target=\"_blank\">seem to be focused</a> on an increase in the Hazard ratio from <a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=147988&amp;p=irol-newsArticle&amp;ID=1739664&amp;highlight=\" target=\"_blank\">results reported last fall</a>. In short: data now suggest an 18% reduction in the risk of death compared to a 31% reduction last September. (<a href=\"https://seekingalpha.com/currents/post/1059711\" target=\"_blank\">previous</a>)</p><div class=\"tiny-share-widget\" data-id=\"1061041\" data-linked=\"Synta Pharmaceuticals (SNTA -34.1%) plummets as the market&#39;s interpretation of results from a...\" data-tweet=\"$MDGL - Synta Pharmaceuticals (SNTA -34.1%) plummets as the market&#39;s interpretation of results from a Phase 2b/3 trial of the Hsp90 inhibitor ganetespib is far less sanguine than the company&#39;s own take on the data. SNTA notes that &quot;the combination of ga... https://seekingalpha.com/news/1061041?source=tweet\" data-url=\"https://seekingalpha.com/news/1061041\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060971\" data-ts=\"1370282759\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OWW\" target=\"_blank\">OWW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060971\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">An upgrade to Buy from Lazard provides a lift to Orbitz (OWW +2%): the firm cites valuation and...</a></h4><p>An <a href=\"http://wallstcheatsheet.com/stocks/analysts-intel-has-room-to-grow-and-3-more-research-notes-to-explore.html/3/\" target=\"_blank\">upgrade to Buy</a> from Lazard provides a lift to Orbitz (<a href=\"https://seekingalpha.com/symbol/OWW\" title=\"Orbitz Worldwide, Inc.\">OWW</a> <font color=\"green\">+2%</font>): the firm cites valuation and improving hotel room bookings growth. Shares are <font color=\"green\">up 178%</font> YTD after <a href=\"https://www.google.com/finance?chdnp=1&amp;chdd=1&amp;chds=1&amp;chdv=1&amp;chvs=maximized&amp;chdeh=0&amp;chfdeh=0&amp;chdet=1369857600000&amp;chddm=239489&amp;chls=IntervalBasedLine&amp;q=NYSE:OWW&amp;ntsp=0&amp;ei=pNqsUbjdPLHEiwLkhgE\" target=\"_blank\">struggling in 2011-2012</a> thanks to share losses to Priceline/Expedia.</p><div class=\"tiny-share-widget\" data-id=\"1060971\" data-linked=\"An upgrade to Buy from Lazard provides a lift to Orbitz (OWW +2%): the firm cites valuation and...\" data-tweet=\"$OWW - An upgrade to Buy from Lazard provides a lift to Orbitz (OWW +2%): the firm cites valuation and improving hotel room bookings growth. Shares are up 178% YTD after struggling in 2011-2012 thanks to share losses to Priceline/Expedia. https://seekingalpha.com/news/1060971?source=tweet\" data-url=\"https://seekingalpha.com/news/1060971\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060781\" data-ts=\"1370281794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CELG\" target=\"_blank\">CELG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060781\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Recently public Receptos (RCPT +19.5%) soars on a Credit Suisse initiation (Outperform, price...</a></h4><p>Recently public Receptos (RCPT <font color=\"green\">+19.5%</font>) soars on a Credit Suisse <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/06/3642300/update-credit-suisse-initiates-receptos-at-outperform-on\" target=\"_blank\">initiation</a> (Outperform, price target $21). Analyst Ravi Mehrotra says RPC1063 \u2014 the company's \"key asset\" \u2014 has a clinical profile that puts it \"in a different 'bucket'\" than Novartis' Gilenya when it comes to treating multiple sclerosis.</p><div class=\"tiny-share-widget\" data-id=\"1060781\" data-linked=\"Recently public Receptos (RCPT +19.5%) soars on a Credit Suisse initiation (Outperform, price...\" data-tweet=\"$CELG - Recently public Receptos (RCPT +19.5%) soars on a Credit Suisse initiation (Outperform, price target $21). Analyst Ravi Mehrotra says RPC1063 \u2014 the company&#39;s &quot;key asset&quot; \u2014 has a clinical profile that puts it &quot;in a different &#39;bucket&#39;&quot; than Novart... https://seekingalpha.com/news/1060781?source=tweet\" data-url=\"https://seekingalpha.com/news/1060781\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060771\" data-ts=\"1370281754\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLNX\" target=\"_blank\">MLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060771\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mellanox (MLNX -4.5%) shareholders shot down a proposal at the company&#39;s annual meeting...</a></h4><p>Mellanox (<a href=\"https://seekingalpha.com/symbol/MLNX\" title=\"Mellanox Technologies, Ltd.\">MLNX</a> <font color=\"red\">-4.5%</font>) shareholders shot down a proposal at the company's annual meeting (<a href=\"https://seekingalpha.com/article/1476791-mellanox-technologies-ltd-shareholder-analyst-call?part=single\" target=\"_blank\">transcript</a>) to allow CEO Eyal Waldman to remain chairman. The news is pressuring shares of the InfiniBand adapter card/switch maker, which fell on Friday thanks to a <a href=\"https://seekingalpha.com/currents/post/1058081\" target=\"_blank\">UBS downgrade note</a> that predicted such an outcome. Look for Mellanox to now begin a search for an independent chairman.</p><div class=\"tiny-share-widget\" data-id=\"1060771\" data-linked=\"Mellanox (MLNX -4.5%) shareholders shot down a proposal at the company&#39;s annual meeting...\" data-tweet=\"$MLNX - Mellanox (MLNX -4.5%) shareholders shot down a proposal at the company&#39;s annual meeting (transcript) to allow CEO Eyal Waldman to remain chairman. The news is pressuring shares of the InfiniBand adapter card/switch maker, which fell on Friday th... https://seekingalpha.com/news/1060771?source=tweet\" data-url=\"https://seekingalpha.com/news/1060771\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060761\" data-ts=\"1370281657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEZS\" target=\"_blank\">AEZS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060761\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aeterna Zentaris (AEZS -4.8%) slips today, despite presenting positive results from trials of...</a></h4><p>Aeterna Zentaris (<a href=\"https://seekingalpha.com/symbol/AEZS\" title=\"AEterna Zentaris, Inc.\">AEZS</a> <font color=\"red\">-4.8%</font>) slips today, despite presenting positive results from trials of the company's prostate cancer treatment earlier today. The company presented final Phase 1 data for its ongoing trial of its lead oncology compound, zoptarelin doxorubicin, showing promising anti-tumor activity in heavily pre-treated men with castration and taxane-resistant prostate cancer.</p><div class=\"tiny-share-widget\" data-id=\"1060761\" data-linked=\"Aeterna Zentaris (AEZS -4.8%) slips today, despite presenting positive results from trials of...\" data-tweet=\"$AEZS - Aeterna Zentaris (AEZS -4.8%) slips today, despite presenting positive results from trials of the company&#39;s prostate cancer treatment earlier today. The company presented final Phase 1 data for its ongoing trial of its lead oncology compound, zo... https://seekingalpha.com/news/1060761?source=tweet\" data-url=\"https://seekingalpha.com/news/1060761\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060751\" data-ts=\"1370281236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMRN\" target=\"_blank\">BMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060751\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leerink analyst Joseph Schwartz comes out in support of BioMarin (BMRN -7.5%) amid a sell-off in...</a></h4><p>Leerink analyst Joseph Schwartz <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/06/3642651/update-leerink-reiterates-outperform-on-biomarin-on-posi\" target=\"_blank\">comes out in support</a> of BioMarin (<a href=\"https://seekingalpha.com/symbol/BMRN\" title=\"BioMarin Pharmaceutical Inc.\">BMRN</a> <font color=\"red\">-7.5%</font>) amid a sell-off in the shares. Results presented at ASCO (<a href=\"https://seekingalpha.com/currents/post/1060361\" target=\"_blank\">previous</a>) were positive he says, noting that response rates for BMN 673 were \"above the 30% threshold.\" Schwartz reiterates an Outperform rating and a $70 price target.</p><div class=\"tiny-share-widget\" data-id=\"1060751\" data-linked=\"Leerink analyst Joseph Schwartz comes out in support of BioMarin (BMRN -7.5%) amid a sell-off in...\" data-tweet=\"$BMRN - Leerink analyst Joseph Schwartz comes out in support of BioMarin (BMRN -7.5%) amid a sell-off in the shares. Results presented at ASCO (previous) were positive he says, noting that response rates for BMN 673 were &quot;above the 30% threshold.&quot; Schwa... https://seekingalpha.com/news/1060751?source=tweet\" data-url=\"https://seekingalpha.com/news/1060751\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060721\" data-ts=\"1370280663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLS\" target=\"_blank\">SLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060721\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galena Biopharma (GALE -4.3%) gives a pipeline update at ASCO, saying that NeuVax continues to...</a></h4><p>Galena Biopharma (GALE <font color=\"red\">-4.3%</font>) gives a pipeline update at ASCO, saying that NeuVax continues to demonstrate \"durable response rates\", and that a companion diagnostic for HER2 screening in women with breast cancer \"increases accuracy.\" It also reported positive results from Phase 1/2a studies of its folate binding protein, HLA-A2, a restricted peptide immunotherapy for treating ovarian and endometrial cancer.</p><div class=\"tiny-share-widget\" data-id=\"1060721\" data-linked=\"Galena Biopharma (GALE -4.3%) gives a pipeline update at ASCO, saying that NeuVax continues to...\" data-tweet=\"$SLS - Galena Biopharma (GALE -4.3%) gives a pipeline update at ASCO, saying that NeuVax continues to demonstrate &quot;durable response rates&quot;, and that a companion diagnostic for HER2 screening in women with breast cancer &quot;increases accuracy.&quot; It also repo... https://seekingalpha.com/news/1060721?source=tweet\" data-url=\"https://seekingalpha.com/news/1060721\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060691\" data-ts=\"1370279205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GAME\" target=\"_blank\">GAME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060691\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shanda (GAME -7.4%) slumps after 51%-owned Korean mobile game developer Actoz Soft prices a...</a></h4><p>Shanda (<a href=\"https://seekingalpha.com/symbol/GAME\" title=\"Shanda Games Ltd\">GAME</a> <font color=\"red\">-7.4%</font>) slumps after 51%-owned Korean mobile game developer Actoz Soft prices a $67.6M stock offering. Actoz, which has developed several hit games for East Asian markets, says it will use the proceeds to make new investments, and to repay a $40M loan owed to Shanda.</p><div class=\"tiny-share-widget\" data-id=\"1060691\" data-linked=\"Shanda (GAME -7.4%) slumps after 51%-owned Korean mobile game developer Actoz Soft prices a...\" data-tweet=\"$GAME - Shanda (GAME -7.4%) slumps after 51%-owned Korean mobile game developer Actoz Soft prices a $67.6M stock offering. Actoz, which has developed several hit games for East Asian markets, says it will use the proceeds to make new investments, and to... https://seekingalpha.com/news/1060691?source=tweet\" data-url=\"https://seekingalpha.com/news/1060691\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060671\" data-ts=\"1370278224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060671\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Isis Pharmaceuticals (ISIS -5.5%) says it&#39;s earned a $10M milestone payment from AstraZeneca&#39;s...</a></h4><p>Isis Pharmaceuticals (ISIS <font color=\"red\">-5.5%</font>) says it's earned a $10M milestone payment from  AstraZeneca's (NYSE:<a href=\"https://seekingalpha.com/symbol/AZN\" title=\"AstraZeneca Group plc\">AZN</a>) decision to add a second development candidate to their collaboration on cancer antisense drugs. ISIS had struck the deal in December to develop therapeutics against five cancer targets, including an exclusive license for <a href=\"https://seekingalpha.com/symbol/AZN\" title=\"AstraZeneca Group plc\">AZN</a> to develop ISIS-STAT3, a drug ISIS was evaluating for treating advanced lymphoma. It's now adding a second development candidate, ISIS-AR(Rx), to the collaboration.</p><div class=\"tiny-share-widget\" data-id=\"1060671\" data-linked=\"Isis Pharmaceuticals (ISIS -5.5%) says it&#39;s earned a $10M milestone payment from AstraZeneca&#39;s...\" data-tweet=\"$IONS $IONS $AZN - Isis Pharmaceuticals (ISIS -5.5%) says it&#39;s earned a $10M milestone payment from AstraZeneca&#39;s (NYSE:AZN) decision to add a second development candidate to their collaboration on cancer antisense drugs. ISIS had struck the deal in Dec... https://seekingalpha.com/news/1060671?source=tweet\" data-url=\"https://seekingalpha.com/news/1060671\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060651\" data-ts=\"1370278122\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AREX\" target=\"_blank\">AREX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060651\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo views Approach Resources&#39; (AREX +2.2%) announced $250M debt offering as a positive...</a></h4><p>Wells Fargo views Approach Resources' (<a href=\"https://seekingalpha.com/symbol/AREX\" title=\"Approach Resources Inc.\">AREX</a> <font color=\"green\">+2.2%</font>) announced <a href=\"http://finance.yahoo.com/news/approach-resources-inc-announces-250-111400239.html\" target=\"_blank\">$250M debt offering</a> as a positive which should put to rest investor fears that AREX spending won't be covered by cash flow and liquidity. Pro forma for the offering, AREX has ~$400M in liquidity, which should bridge a capital outspend beyond 2014 at current projected capex levels of $260M in 2013 and $300M in 2014, the firm says.</p><div class=\"tiny-share-widget\" data-id=\"1060651\" data-linked=\"Wells Fargo views Approach Resources&#39; (AREX +2.2%) announced $250M debt offering as a positive...\" data-tweet=\"$AREX - Wells Fargo views Approach Resources&#39; (AREX +2.2%) announced $250M debt offering as a positive which should put to rest investor fears that AREX spending won&#39;t be covered by cash flow and liquidity. Pro forma for the offering, AREX has ~$400M in... https://seekingalpha.com/news/1060651?source=tweet\" data-url=\"https://seekingalpha.com/news/1060651\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060631\" data-ts=\"1370277991\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMR\" target=\"_blank\">IMMR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060631\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immersion (IMMR -6.8%) slumps after CEO Victor Viegas discloses he sold 148.2K shares last week...</a></h4><p>Immersion (<a href=\"https://seekingalpha.com/symbol/IMMR\" title=\"Immersion Corporation\">IMMR</a> <font color=\"red\">-6.8%</font>) slumps after CEO Victor Viegas discloses he sold 148.2K shares last week at prices above $15; the sales were tied to the exercising of stock options sporting $7 strike prices. Shares of the haptic feedback tech provider remain <font color=\"green\">up 109%</font> YTD, aided by a <a href=\"https://seekingalpha.com/currents/post/994821\" target=\"_blank\">Q1 beat</a> and a <a href=\"https://seekingalpha.com/currents/post/874281\" target=\"_blank\">March licensing deal</a> with Samsung. (<a href=\"http://www.sec.gov/Archives/edgar/data/1058811/000114036113023656/xslF345X03/doc1.xml\" target=\"_blank\">Form 4</a>)</p><div class=\"tiny-share-widget\" data-id=\"1060631\" data-linked=\"Immersion (IMMR -6.8%) slumps after CEO Victor Viegas discloses he sold 148.2K shares last week...\" data-tweet=\"$IMMR - Immersion (IMMR -6.8%) slumps after CEO Victor Viegas discloses he sold 148.2K shares last week at prices above $15; the sales were tied to the exercising of stock options sporting $7 strike prices. Shares of the haptic feedback tech provider re... https://seekingalpha.com/news/1060631?source=tweet\" data-url=\"https://seekingalpha.com/news/1060631\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060621\" data-ts=\"1370277818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFFY\" target=\"_blank\">AFFY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060621\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Affymax (OTC:AFFY -19.3%) will be delisted by Nasdaq at the close of Wednesday&#39;s trading, after...</a></h4>Affymax (<a href='https://seekingalpha.com/symbol/AFFY' title='Affymax, Inc.'>OTC:AFFY</a> <font color=\"red\">-19.3%</font>) will be delisted by Nasdaq at the close of Wednesday's trading, after the biotech developer declined to appeal <a target=\"_blank\" href=\"https://seekingalpha.com/market_currents/post/1058621\">a ruling</a> that \"the company no longer has an operating business\" and is instead a \"public shell\" due to the recall of its anemia drug Omontys. The company also announced that it was <a target=\"_blank\" href=\"http://www.sec.gov/Archives/edgar/data/1158223/000110465913046137/a13-14193_28k.htm\">paying out</a> $6M to two suppliers of the drug's ingredients.<div class=\"tiny-share-widget\" data-id=\"1060621\" data-linked=\"Affymax (OTC:AFFY -19.3%) will be delisted by Nasdaq at the close of Wednesday&#39;s trading, after...\" data-tweet=\"$AFFY - Affymax (OTC:AFFY -19.3%) will be delisted by Nasdaq at the close of Wednesday&#39;s trading, after the biotech developer declined to appeal a ruling that &quot;the company no longer has an operating business&quot; and is instead a &quot;public shell&quot; due to the r... https://seekingalpha.com/news/1060621?source=tweet\" data-url=\"https://seekingalpha.com/news/1060621\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060601\" data-ts=\"1370277269\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060601\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix (NFLX -3.4%) is seeing more profit-taking on a down day for tech. Over the weekend, SA...</a></h4><p>Netflix (<a href=\"https://seekingalpha.com/symbol/NFLX\" title=\"Netflix, Inc.\">NFLX</a> <font color=\"red\">-3.4%</font>) is seeing more profit-taking on a down day for tech. Over the weekend, SA contributor <a href=\"https://seekingalpha.com/article/1475391-hulu-buyout-could-expose-extreme-netflix-valuation\" target=\"_blank\">Money Investor</a> noted the valuations being thrown around for Hulu (Bloomberg has reported of <a href=\"https://seekingalpha.com/currents/post/1058931\" target=\"_blank\">$1B+ offers</a>) imply a major price/sales discount relative to Netflix's current valuation of 2.8x 2013E sales. One could also point out they appear to be below the <a href=\"https://seekingalpha.com/currents/post/585051\" target=\"_blank\">$2B valuation</a> Providence Equity obtained last fall for its 10% Hulu stake. On the other hand, Netflix has been soundly outgrowing Hulu, and its <em>paid subscriber base</em> <a href=\"http://www.businessinsider.com/its-time-to-admit-that-hulu-is-a-failure-2012-12\" target=\"_blank\">is now bigger</a> than Hulu's estimated <em>total viewer base</em>.</p><div class=\"tiny-share-widget\" data-id=\"1060601\" data-linked=\"Netflix (NFLX -3.4%) is seeing more profit-taking on a down day for tech. Over the weekend, SA...\" data-tweet=\"$NFLX - Netflix (NFLX -3.4%) is seeing more profit-taking on a down day for tech. Over the weekend, SA contributor Money Investor noted the valuations being thrown around for Hulu (Bloomberg has reported of $1B+ offers) imply a major price/sales discoun... https://seekingalpha.com/news/1060601?source=tweet\" data-url=\"https://seekingalpha.com/news/1060601\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060571\" data-ts=\"1370277141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASRT\" target=\"_blank\">ASRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060571\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The FDA&#39;s rejection of Depomed&#39;s (DEPO +6.2%) Sefelsa appears to be a non-event. Results of the...</a></h4><p>The <a href=\"https://seekingalpha.com/market_currents/post/1058971\" target=\"_blank\">FDA's rejection</a> of Depomed's (DEPO <font color=\"green\">+6.2%</font>) Sefelsa appears to be a non-event. Results of the FDA panel <a href=\"https://seekingalpha.com/market_currents/post/865281\" target=\"_blank\">actually came out</a> in early March, in which the majority <a href=\"https://seekingalpha.com/market_currents/post/865161\" target=\"_blank\">voted against approval</a> (13-1 against sufficient evidence of efficacy, 12-2 against risk/benefit profile).</p><div class=\"tiny-share-widget\" data-id=\"1060571\" data-linked=\"The FDA&#39;s rejection of Depomed&#39;s (DEPO +6.2%) Sefelsa appears to be a non-event. Results of the...\" data-tweet=\"$ASRT - The FDA&#39;s rejection of Depomed&#39;s (DEPO +6.2%) Sefelsa appears to be a non-event. Results of the FDA panel actually came out in early March, in which the majority voted against approval (13-1 against sufficient evidence of efficacy, 12-2 against ... https://seekingalpha.com/news/1060571?source=tweet\" data-url=\"https://seekingalpha.com/news/1060571\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060551\" data-ts=\"1370276393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060551\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook (FB -1.9%) slumps once again after Wells Fargo resumes coverage with an Outperform, but...</a></h4>Facebook (<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a> <font color=\"red\">-1.9%</font>) slumps once again after <a target=\"_blank\" href=\"http://www.streetinsider.com/Analyst+Comments/Wells+Fargo+Assumes+Facebook+%28FB%29+at+Outperform%2C+Lowers+PT/8384931.html\">Wells Fargo</a> resumes coverage with an Outperform, but lowers its valuation range to $30-$32 from $36-$39, and also cuts its 2014 revenue and EPS forecasts to $8.24B and $0.75 from $8.5B and $0.80 (2013 estimates have been slightly raised). Analyst Peter Stabler is optimistic about the rise of <a target=\"_blank\" href=\"http://en.wikipedia.org/wiki/Native_advertising\">native ad formats</a> (such as Facebook's <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/519971\">Sponsored Stories</a>), and a migration away from \"broadcast\" formats (such as traditional banner ads). But his bullishness is tempered by \"the challenges associated with the launch of new communication forms and the time required for marketplace education.\"<div class=\"tiny-share-widget\" data-id=\"1060551\" data-linked=\"Facebook (FB -1.9%) slumps once again after Wells Fargo resumes coverage with an Outperform, but...\" data-tweet=\"$FB - Facebook (FB -1.9%) slumps once again after Wells Fargo resumes coverage with an Outperform, but lowers its valuation range to $30-$32 from $36-$39, and also cuts its 2014 revenue and EPS forecasts to $8.24B and $0.75 from $8.5B and $0.80 (2013 es... https://seekingalpha.com/news/1060551?source=tweet\" data-url=\"https://seekingalpha.com/news/1060551\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060531\" data-ts=\"1370275494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMY\" target=\"_blank\">BMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060531\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs&#39; analyst Jami Rubin weighs in on Bristol-Myers&#39; (BMY +5.6%) after its ASCO...</a></h4><p>Goldman Sachs' analyst Jami Rubin <a href=\"http://www.streetinsider.com/Analyst+Comments/Bristol-Myers+Squibb+%28BMY%29+Immuno-Oncology+Paradigm+Changing+-+Goldman/8385152.html\" target=\"_blank\">weighs in</a> on Bristol-Myers' (<a href=\"https://seekingalpha.com/symbol/BMY\" title=\"Bristol-Myers Squibb Company\">BMY</a> <font color=\"green\">+5.6%</font>) after its ASCO presentation today, calling the drug giants immuno-oncology program \"paradigm changing\" and raising its price target on the shares to $55 from $48. \"No doubt, immuno-oncology will be the dominant 'story' in cancer for the next 3-5 years,\" Rubin says, noting that the market is likely to be massive, and <a href=\"https://seekingalpha.com/symbol/BMY\" title=\"Bristol-Myers Squibb Company\">BMY</a> is the best leveraged to capitalize on the opportunity. The firm reiterates its Conviction Buy.</p><div class=\"tiny-share-widget\" data-id=\"1060531\" data-linked=\"Goldman Sachs&#39; analyst Jami Rubin weighs in on Bristol-Myers&#39; (BMY +5.6%) after its ASCO...\" data-tweet=\"$BMY - Goldman Sachs&#39; analyst Jami Rubin weighs in on Bristol-Myers&#39; (BMY +5.6%) after its ASCO presentation today, calling the drug giants immuno-oncology program &quot;paradigm changing&quot; and raising its price target on the shares to $55 from $48. &quot;No doubt... https://seekingalpha.com/news/1060531?source=tweet\" data-url=\"https://seekingalpha.com/news/1060531\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060481\" data-ts=\"1370274750\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAIN\" target=\"_blank\">MAIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060481\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Business development companies (BDCS -1.1%) see some selling as higher interest rates threaten...</a></h4><p>Business development companies (<a href=\"https://seekingalpha.com/symbol/BDCS\" title=\"UBS ETRACS Wells Fargo Business Development Company ETN\">BDCS</a> <font color=\"red\">-1.1%</font>) see some selling as higher interest rates threaten to offer at least minor competition to their fat dividends. The <a href=\"https://seekingalpha.com/currents/post/1058341\" target=\"_blank\">drop in junk bond prices</a> - a decent proxy for the assets on their books - isn't helping either. Leading on the downside today: Main Street (<a href=\"https://seekingalpha.com/symbol/MAIN\" title=\"Main Street Capital\">MAIN</a> <font color=\"red\">-4.5%</font>), American Capital (<a href=\"https://seekingalpha.com/symbol/ACAS\" title=\"American Capital\">ACAS</a> <font color=\"red\">-2.4%</font>), Prospect Capital (<a href=\"https://seekingalpha.com/symbol/PSEC\" title=\"Prospect Capital Corporation\">PSEC</a> <font color=\"red\">-1.4%</font>), Ares Capital (<a href=\"https://seekingalpha.com/symbol/ARCC\" title=\"Ares Capital\">ARCC</a> <font color=\"red\">-1.1%</font>), Blackrock Kelso (<a href=\"https://seekingalpha.com/symbol/BKCC\" title=\"BlackRock Capital Investment Corporation\">BKCC</a> <font color=\"red\">-1.1%</font>).</p><div class=\"tiny-share-widget\" data-id=\"1060481\" data-linked=\"Business development companies (BDCS -1.1%) see some selling as higher interest rates threaten...\" data-tweet=\"$MAIN $BDCS $MAIN - Business development companies (BDCS -1.1%) see some selling as higher interest rates threaten to offer at least minor competition to their fat dividends. The drop in junk bond prices - a decent proxy for the assets on their books - ... https://seekingalpha.com/news/1060481?source=tweet\" data-url=\"https://seekingalpha.com/news/1060481\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060471\" data-ts=\"1370274665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEI\" target=\"_blank\">HEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060471\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heico (HEI +1.7%) says its Flight Support Group has completed its acquisition of Reinhold...</a></h4><p>Heico (<a href=\"https://seekingalpha.com/symbol/HEI\" title=\"HEICO Corporation\">HEI</a> <font color=\"green\">+1.7%</font>) says its Flight Support Group has completed its acquisition of Reinhold Industries from The Jordan Company. Reinhold's management will remain with the company and it doesn't expect any employee turnover as a result of the acquisition. Financial details were not disclosed, but it expects the purchase to be accretive to earnings in the first 12 months following the closing.</p><div class=\"tiny-share-widget\" data-id=\"1060471\" data-linked=\"Heico (HEI +1.7%) says its Flight Support Group has completed its acquisition of Reinhold...\" data-tweet=\"$HEI - Heico (HEI +1.7%) says its Flight Support Group has completed its acquisition of Reinhold Industries from The Jordan Company. Reinhold&#39;s management will remain with the company and it doesn&#39;t expect any employee turnover as a result of the acquis... https://seekingalpha.com/news/1060471?source=tweet\" data-url=\"https://seekingalpha.com/news/1060471\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060461\" data-ts=\"1370274573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HALO\" target=\"_blank\">HALO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060461\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">As promised, Halozyme Therapeutics (HALO -4.4%) reports what it says is &quot;positive&quot; data from a...</a></h4><p>As promised, Halozyme Therapeutics (<a href=\"https://seekingalpha.com/symbol/HALO\" title=\"Halozyme Therapeutics, Inc.\">HALO</a> <font color=\"red\">-4.4%</font>) reports what it says is \"positive\" data from a Phase 1b trial of a PEGPH20/ gemcitabine combo for the treatment of stage IV metastatic pancreatic cancer. The stock, which <a href=\"https://seekingalpha.com/currents/post/1032601\" target=\"_blank\">rose markedly</a> on May 16 when the company announced it would present results from the trial at ASCO, isn't faring as well today. The overall response rate (RECIST) was 42% \"for those treated at therapeutic dose levels.\" (PR)</p><div class=\"tiny-share-widget\" data-id=\"1060461\" data-linked=\"As promised, Halozyme Therapeutics (HALO -4.4%) reports what it says is &quot;positive&quot; data from a...\" data-tweet=\"$HALO - As promised, Halozyme Therapeutics (HALO -4.4%) reports what it says is &quot;positive&quot; data from a Phase 1b trial of a PEGPH20/ gemcitabine combo for the treatment of stage IV metastatic pancreatic cancer. The stock, which rose markedly on May 16 wh... https://seekingalpha.com/news/1060461?source=tweet\" data-url=\"https://seekingalpha.com/news/1060461\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060441\" data-ts=\"1370274200\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060441\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amgen (AMGN -3.1%) slips today as analysts give a muted response to its experimental skin-cancer...</a></h4><p>Amgen (<a href=\"https://seekingalpha.com/symbol/AMGN\" title=\"Amgen Inc.\">AMGN</a> <font color=\"red\">-3.1%</font>) slips today as analysts give a muted response to its experimental skin-cancer drug, T-Vec, despite delivering better-than-expected <a target=\"_blank\" href=\"http://www.streetinsider.com/Press+Releases/Amgen+Presents+Positive+Results+From+Talimogene+Laherparepvec+Phase+3+Study+In+Patients+With+Metastatic+Melanoma/8383522.html\">study data at ASCO</a>. The problem is a new class of PD-1 immunotherapy drugs from Merck (NYSE:<a href=\"https://seekingalpha.com/symbol/MRK\" title=\"Merck &amp; Co Inc.\">MRK</a>) and Bristol-Myers (NYSE:<a href=\"https://seekingalpha.com/symbol/BMY\" title=\"Bristol-Myers Squibb Company\">BMY</a>) are <a target=\"_blank\" href=\"https://seekingalpha.com/market_currents/post/1059631\">dominating the field</a>. RBC predicts they'll \"eventually usher in new standard of care\" for melanoma, and limiting T-Vec's sales potential to only around $300M to $500M annually - which isn't much considering the multibillion-dollar market potential for PD-1 drugs.</p><div class=\"tiny-share-widget\" data-id=\"1060441\" data-linked=\"Amgen (AMGN -3.1%) slips today as analysts give a muted response to its experimental skin-cancer...\" data-tweet=\"$AMGN $AMGN $MRK - Amgen (AMGN -3.1%) slips today as analysts give a muted response to its experimental skin-cancer drug, T-Vec, despite delivering better-than-expected study data at ASCO. The problem is a new class of PD-1 immunotherapy drugs from Merc... https://seekingalpha.com/news/1060441?source=tweet\" data-url=\"https://seekingalpha.com/news/1060441\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060421\" data-ts=\"1370274089\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNQ\" target=\"_blank\">CNQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060421\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canadian Natural&amp;nbsp;Resources (CNQ -1.9%) is cut to Sell from Neutral with a $28 price target...</a></h4><p>Canadian NaturalResources (<a href=\"https://seekingalpha.com/symbol/CNQ\" title=\"Canadian Natural Resources, Ltd.\">CNQ</a> <font color=\"red\">-1.9%</font>) is <a href=\"http://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Goldman+Downgrades+Canadian+Natural+Resources+Limited+%28CNQ%29+to+Sell/8384675.html\" target=\"_blank\">cut to Sell</a> from Neutral with a $28 price target (from $33) at GoldmanSachs, which believes higher normalized earnings and asset value estimates will be masked by WCS pricing concerns during 2014-15. The firm still has a favorable long-term outlook for CNQ.</p><div class=\"tiny-share-widget\" data-id=\"1060421\" data-linked=\"Canadian NaturalResources (CNQ -1.9%) is cut to Sell from Neutral with a $28 price target (from...\" data-tweet=\"$CNQ - Canadian NaturalResources (CNQ -1.9%) is cut to Sell from Neutral with a $28 price target (from $33) at GoldmanSachs, which believes higher normalized earnings and asset value estimates will be masked by WCS pricing concerns during 2014-15. The... https://seekingalpha.com/news/1060421?source=tweet\" data-url=\"https://seekingalpha.com/news/1060421\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060401\" data-ts=\"1370273569\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TVTY\" target=\"_blank\">TVTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060401\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Piper Jaffray&#39;s upgrade of Healthways (HWAY +10.7%) which has the stock trading up...</a></h4><p>More on Piper Jaffray's <a href=\"https://seekingalpha.com/currents/post/1059551\" target=\"_blank\">upgrade</a> of Healthways (HWAY <font color=\"green\">+10.7%</font>) which has the stock trading up double-digits: The company \"will be a leader in the rapidly growing population health management segment,\" analyst Sean Wieland says, adding that \"HWAY is <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/06/3641178/update-piper-jaffray-upgrades-healthways-to-overweight-o\" target=\"_blank\">the domain expert</a> in population health management, yet has less than a 1% market share in the $1B per year opportunity\" represented by Accountable Care Organizations.</p><div class=\"tiny-share-widget\" data-id=\"1060401\" data-linked=\"More on Piper Jaffray&#39;s upgrade of Healthways (HWAY +10.7%) which has the stock trading up...\" data-tweet=\"$TVTY - More on Piper Jaffray&#39;s upgrade of Healthways (HWAY +10.7%) which has the stock trading up double-digits: The company &quot;will be a leader in the rapidly growing population health management segment,&quot; analyst Sean Wieland says, adding that &quot;HWAY is... https://seekingalpha.com/news/1060401?source=tweet\" data-url=\"https://seekingalpha.com/news/1060401\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060371\" data-ts=\"1370273071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WETF\" target=\"_blank\">WETF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060371\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The yen (FXY +1.4%) surges higher, with dollar/yen crashing through &amp;yen;100 all the way to...</a></h4><p>The yen (<a href=\"https://seekingalpha.com/symbol/FXY\" title=\"Invesco CurrencyShares Japanese Yen Trust ETF\">FXY</a> <font color=\"green\">+1.4%</font>) surges higher, with <a href=\"http://finviz.com/forex_charts.ashx?t=USDJPY\" target=\"_blank\">dollar/yen crashing through 100</a> all the way to 98.97 - the first time in double digits in about a month. Along with the strengthening yen are declining Nikkei 225 futures (NYSEARCA:<a href=\"https://seekingalpha.com/symbol/NKY\" title=\"Precidian MAXIS Nikkei 225 Index ETF\">NKY</a>), <font color=\"red\">off 2.8%</font>. <a href=\"https://seekingalpha.com/symbol/EWJ\" title=\"iShares MSCI Japan ETF\">EWJ</a> <font color=\"red\">-1.9%</font>, <a href=\"https://seekingalpha.com/symbol/DXJ\" title=\"WisdomTree Japan Hedged Equity ETF\">DXJ</a> <font color=\"red\">-3.6%</font>. The proprietor of the DXJ, WisdomTree (<a href=\"https://seekingalpha.com/symbol/WETF\" title=\"WisdomTree Investments, Inc.\">WETF</a> <font color=\"red\">-3.1%</font>).</p><div class=\"tiny-share-widget\" data-id=\"1060371\" data-linked=\"The yen (FXY +1.4%) surges higher, with dollar/yen crashing through 100 all the way to 98.97 -...\" data-tweet=\"$WETF $FXY $NKY - The yen (FXY +1.4%) surges higher, with dollar/yen crashing through 100 all the way to 98.97 - the first time in double digits in about a month. Along with the strengthening yen are declining Nikkei 225 futures (NYSEARCA:NKY), off 2.... https://seekingalpha.com/news/1060371?source=tweet\" data-url=\"https://seekingalpha.com/news/1060371\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060361\" data-ts=\"1370272849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BMRN\" target=\"_blank\">BMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060361\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shares of BioMarin (BMRN -8.1%) sink in morning trading. Data presented at ASCO from an ongoing...</a></h4><p>Shares of BioMarin (<a href=\"https://seekingalpha.com/symbol/BMRN\" title=\"BioMarin Pharmaceutical Inc.\">BMRN</a> <font color=\"red\">-8.1%</font>) sink in morning trading. Data presented at ASCO from an ongoing clinical trial of the PARP inhibitor BMN 673 showed RECIST rates of 44% and 39% for 28 gBRCA ovarian cancer patients and 18 gBRCA breast cancer patients respectively. In a note published Friday, Credit Suisse (Neutral, PT $68) <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/13/05/3637135/update-credit-suisse-initiates-biomarin-pharmaceutical-a\" target=\"_blank\">assigned a risk adjustment</a> of 50% to BMN 673 when modeling contributions from BMRN's pipeline.</p><div class=\"tiny-share-widget\" data-id=\"1060361\" data-linked=\"Shares of BioMarin (BMRN -8.1%) sink in morning trading. Data presented at ASCO from an ongoing...\" data-tweet=\"$BMRN - Shares of BioMarin (BMRN -8.1%) sink in morning trading. Data presented at ASCO from an ongoing clinical trial of the PARP inhibitor BMN 673 showed RECIST rates of 44% and 39% for 28 gBRCA ovarian cancer patients and 18 gBRCA breast cancer patie... https://seekingalpha.com/news/1060361?source=tweet\" data-url=\"https://seekingalpha.com/news/1060361\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060241\" data-ts=\"1370270746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060241\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesla (TSLA -5.2%) dives again as investors pocket some more of their huge spring gains; shares...</a></h4><p>Tesla (<a href=\"https://seekingalpha.com/symbol/TSLA\" title=\"Tesla, Inc.\">TSLA</a> <font color=\"red\">-5.2%</font>) dives again as investors pocket some more of their huge spring gains; shares are now off 19% from last Wednesday's high of $114.90, but remain up 173% YTD. The company has <a href=\"http://www.cnbc.com/id/100780498\" target=\"_blank\">made a believer</a> out of Jim Cramer, who gushed about the Model S on Friday night's episode of <em>Mad Money</em> after taking a test-drive. \"All I can say is 'wow,' I want one. It is that terrific. It was the best, most quiet and most powerful ride I ever had.\" However, Cramer isn't as enthusiastic about Tesla's valuation.</p><div class=\"tiny-share-widget\" data-id=\"1060241\" data-linked=\"Tesla (TSLA -5.2%) dives again as investors pocket some more of their huge spring gains; shares...\" data-tweet=\"$TSLA - Tesla (TSLA -5.2%) dives again as investors pocket some more of their huge spring gains; shares are now off 19% from last Wednesday&#39;s high of $114.90, but remain up 173% YTD. The company has made a believer out of Jim Cramer, who gushed about th... https://seekingalpha.com/news/1060241?source=tweet\" data-url=\"https://seekingalpha.com/news/1060241\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060211\" data-ts=\"1370270409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSRO\" target=\"_blank\">TSRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060211\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesaro (TSRO +13.6%) says it&#39;s partnering with the Breast International Group and the European...</a></h4><p>Tesaro (<a href=\"https://seekingalpha.com/symbol/TSRO\" title=\"Tesaro\">TSRO</a> <font color=\"green\">+13.6%</font>) says <a href=\"http://www.streetinsider.com/Press+Releases/TESARO%2C+Breast+International+Group+%28BIG%29%2C+and+the+European+Organization+for+Research+and+Treatment+of+Cancer+%28EORTC%29+Announce+Collaboration+for+Niraparib+Clinical+Development+in+Breast+Cancer/8383980.html\" target=\"_blank\">it's partnering</a> with the Breast International Group and the European Organization for Research and Treatment of Cancer for the Phase 3 clinical development of Niraparib, an oral, poly polymerase inhibitor for the treatment of breast cancer. The partnership plans to leverage its extensive scientific and clinical expertise and its network of hospitals and oncology research centers around the world to accelerate the clinical trials.</p><div class=\"tiny-share-widget\" data-id=\"1060211\" data-linked=\"Tesaro (TSRO +13.6%) says it&#39;s partnering with the Breast International Group and the European...\" data-tweet=\"$TSRO - Tesaro (TSRO +13.6%) says it&#39;s partnering with the Breast International Group and the European Organization for Research and Treatment of Cancer for the Phase 3 clinical development of Niraparib, an oral, poly polymerase inhibitor for the treatm... https://seekingalpha.com/news/1060211?source=tweet\" data-url=\"https://seekingalpha.com/news/1060211\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060201\" data-ts=\"1370270359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALSK\" target=\"_blank\">ALSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060201\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alaska Communications (ALSK +4.3%) gets a lift from SA Pro&#39;s Harry Long&#39;s still-embargoed piece...</a></h4><p>Alaska Communications (<a href=\"https://seekingalpha.com/symbol/ALSK\" title=\"Alaska Communications Systems Group, Inc.\">ALSK</a> <font color=\"green\">+4.3%</font>) gets a lift from SA Pro's Harry Long's still-embargoed piece suggesting the company's strong cash flow amid a beaten-down share price makes it <a href=\"https://seekingalpha.com/article/1476091-alaska-communications-is-an-excellent-takeover-target\" target=\"_blank\">an excellent takeover</a> target.</p><div class=\"tiny-share-widget\" data-id=\"1060201\" data-linked=\"Alaska Communications (ALSK +4.3%) gets a lift from SA Pro&#39;s Harry Long&#39;s still-embargoed piece...\" data-tweet=\"$ALSK - Alaska Communications (ALSK +4.3%) gets a lift from SA Pro&#39;s Harry Long&#39;s still-embargoed piece suggesting the company&#39;s strong cash flow amid a beaten-down share price makes it an excellent takeover target. https://seekingalpha.com/news/1060201?source=tweet\" data-url=\"https://seekingalpha.com/news/1060201\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060181\" data-ts=\"1370270187\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060181\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rio Tinto (RIO +2.4%) is said to be pursuing an IPO of its gem unit, the world&#39;s largest...</a></h4>Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color=\"green\">+2.4%</font>) is said to be <a target=\"_blank\" href=\"http://www.bloomberg.com/news/2013-06-03/rio-tinto-said-to-favor-diamond-ipo-after-failing-to-find-buyer.html\">pursuing an IPO</a> of its gem unit, the world's largest supplier of natural colored diamonds, after failing to find a buyer. RIO is working on asset sales and cutting staff as waning global demand for commodities is crimping revenue across the sector.<div class=\"tiny-share-widget\" data-id=\"1060181\" data-linked=\"Rio Tinto (RIO +2.4%) is said to be pursuing an IPO of its gem unit, the world&#39;s largest...\" data-tweet=\"$RIO - Rio Tinto (RIO +2.4%) is said to be pursuing an IPO of its gem unit, the world&#39;s largest supplier of natural colored diamonds, after failing to find a buyer. RIO is working on asset sales and cutting staff as waning global demand for commodities ... https://seekingalpha.com/news/1060181?source=tweet\" data-url=\"https://seekingalpha.com/news/1060181\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060141\" data-ts=\"1370269573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRIP\" target=\"_blank\">TRIP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060141\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel cuts TripAdvisor (TRIP -3.2%) to Hold on account of valuation; the firm notes shares have...</a></h4><a href=\"http://finance.yahoo.com/news/analysts-actions-atu-ffiv-intc-121400949.html\" target=\"_blank\">Stifel cuts</a> TripAdvisor (<a href='https://seekingalpha.com/symbol/TRIP' title='TripAdvisor Inc.'>TRIP</a> <font color='red'>-3.2%</font>) to Hold on account of valuation; the firm notes shares have blown past its $58 PT. TripAdvisor trades at 37x 2013E EPS, and is still <font color=\"green\">up 49%</font> YTD.<div class=\"tiny-share-widget\" data-id=\"1060141\" data-linked=\"Stifel cuts TripAdvisor (TRIP -3.2%) to Hold on account of valuation; the firm notes shares have...\" data-tweet=\"$TRIP - Stifel cuts TripAdvisor (TRIP -3.2%) to Hold on account of valuation; the firm notes shares have blown past its $58 PT. TripAdvisor trades at 37x 2013E EPS, and is still up 49% YTD. https://seekingalpha.com/news/1060141?source=tweet\" data-url=\"https://seekingalpha.com/news/1060141\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060131\" data-ts=\"1370269106\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDD\" target=\"_blank\">DDD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060131\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">3D printer makers 3D Systems (DDD -4.7%), Stratasys (SSYS -6.2%), and ExOne (XONE -5.7%) are...</a></h4><p>3D printer makers 3D Systems (<a href=\"https://seekingalpha.com/symbol/DDD\" title=\"3D Systems Corp.\">DDD</a> <font color=\"red\">-4.7%</font>), Stratasys (<a href=\"https://seekingalpha.com/symbol/SSYS\" title=\"Stratasys, Inc.\">SSYS</a> <font color=\"red\">-6.2%</font>), and ExOne (<a href=\"https://seekingalpha.com/symbol/XONE\" title=\"ExOne\">XONE</a> <font color=\"red\">-5.7%</font>) are slumping, possibly with the help of <a href=\"https://seekingalpha.com/article/1475161-cramer-s-lightning-round-component-plays-are-dangerous-5-31-13\" target=\"_blank\">critical comments</a> from Jim Cramer. Asked about 3D Systems, Cramer replied, \"It is not my favorite. I think 3D stocks are vulnerable to profit taking. Let's be very careful.\"</p><div class=\"tiny-share-widget\" data-id=\"1060131\" data-linked=\"3D printer makers 3D Systems (DDD -4.7%), Stratasys (SSYS -6.2%), and ExOne (XONE -5.7%) are...\" data-tweet=\"$DDD $DDD $SSYS - 3D printer makers 3D Systems (DDD -4.7%), Stratasys (SSYS -6.2%), and ExOne (XONE -5.7%) are slumping, possibly with the help of critical comments from Jim Cramer. Asked about 3D Systems, Cramer replied, &quot;It is not my favorite. I think... https://seekingalpha.com/news/1060131?source=tweet\" data-url=\"https://seekingalpha.com/news/1060131\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060111\" data-ts=\"1370268779\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/P\" target=\"_blank\">P</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060111\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pandora (P -6.3%) slumps following reports Apple has struck an iRadio licensing deal with Warner...</a></h4><p>Pandora (<a href=\"https://seekingalpha.com/symbol/P\" title=\"Pandora Media\">P</a> <font color=\"red\">-6.3%</font>) slumps following reports Apple has struck an <a href=\"https://seekingalpha.com/currents/post/1059171\" target=\"_blank\">iRadio licensing deal </a>with Warner Music, and is trying to wrap up deals in time to announce the service at the June 10-14 WWDC conference. Apple still reportedly needs a publishing rights deal with Universal Music (a recorded music deal is said to have been struck), and publishing and recorded music deals with Sony. Two things still working in Pandora's favor: the time invested by its users in creating custom stations (creates a switching cost), and the fact Apple's service is expected to only work on Apple hardware (many Pandora users rely on both Apple and non-Apple hardware). (<a href=\"https://seekingalpha.com/currents/search?query=apple%20pandora\" target=\"_blank\">previous</a>)</p><div class=\"tiny-share-widget\" data-id=\"1060111\" data-linked=\"Pandora (P -6.3%) slumps following reports Apple has struck an iRadio licensing deal with Warner...\" data-tweet=\"$P - Pandora (P -6.3%) slumps following reports Apple has struck an iRadio licensing deal with Warner Music, and is trying to wrap up deals in time to announce the service at the June 10-14 WWDC conference. Apple still reportedly needs a publishing righ... https://seekingalpha.com/news/1060111?source=tweet\" data-url=\"https://seekingalpha.com/news/1060111\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060041\" data-ts=\"1370267908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060041\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar Therapeutics (NKTR -3.1%) falls despite the company&#39;s presentation at ASCO during which...</a></h4><p>Nektar Therapeutics (<a href=\"https://seekingalpha.com/symbol/NKTR\" title=\"Nektar Therapeutics\">NKTR</a> <font color=\"red\">-3.1%</font>) falls despite the company's presentation at ASCO during which Chief Scientific Officer <span class=\"person\">Stephen Doberstein</span> describes preclinical data for the investigational cancer treatment NKTR-214 as \"positive.\" (PR)</p><div class=\"tiny-share-widget\" data-id=\"1060041\" data-linked=\"Nektar Therapeutics (NKTR -3.1%) falls despite the company&#39;s presentation at ASCO during which...\" data-tweet=\"$NKTR - Nektar Therapeutics (NKTR -3.1%) falls despite the company&#39;s presentation at ASCO during which Chief Scientific Officer Stephen Doberstein describes preclinical data for the investigational cancer treatment NKTR-214 as &quot;positive.&quot; (PR) https://seekingalpha.com/news/1060041?source=tweet\" data-url=\"https://seekingalpha.com/news/1060041\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060011\" data-ts=\"1370267399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060011\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clovis Oncology (NASDAQ:CLVS) soars 77% after saying that its CO-1686 lung-cancer drug has...</a></h4><p>Clovis Oncology (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CLVS\" title=\"Clovis Oncology\">CLVS</a>) <font color=\"green\">soars 77%</font> after saying that its CO-1686 lung-cancer drug has offered \"clear evidence of meaningful activity in a heavily pre-treated patient population\" in an ongoing Phase I/II trial. \"Metastasis shrinkage has been observed at multiple organ sites,\" including in the brain and liver. \"I guess <a href=\"https://twitter.com/adamfeuerstein/status/341548360991395841\" target=\"_blank\">we were all wrong</a>,\" tweets Adam Feuerstein. \"$CLVS wins #ASCO13.\" (PR)</p><div class=\"tiny-share-widget\" data-id=\"1060011\" data-linked=\"Clovis Oncology (NASDAQ:CLVS) soars 77% after saying that its CO-1686 lung-cancer drug has...\" data-tweet=\"$CLVS - Clovis Oncology (NASDAQ:CLVS) soars 77% after saying that its CO-1686 lung-cancer drug has offered &quot;clear evidence of meaningful activity in a heavily pre-treated patient population&quot; in an ongoing Phase I/II trial. &quot;Metastasis shrinkage has been... https://seekingalpha.com/news/1060011?source=tweet\" data-url=\"https://seekingalpha.com/news/1060011\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1060001\" data-ts=\"1370267309\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FFIV\" target=\"_blank\">FFIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1060001\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">13 months after launching coverage with an Overweight and $155 PT, Morgan Stanley downgrades F5...</a></h4>13 months after <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/12/04/2518439/update-morgan-stanley-initiates-f5-networks-at-overweigh\" target=\"_blank\">launching coverage</a> with an Overweight and $155 PT, Morgan Stanley downgrades F5 (<a href='https://seekingalpha.com/symbol/FFIV' title='F5 Networks, Inc.'>FFIV</a> <font color='red'>-4.4%</font>) to Equal Weight, sending shares below $80. <a href=\"https://twitter.com/VetTechTrader/status/341546823682510851\" target=\"_blank\">The firm cites</a> valuation, a maturing application delivery controller &#40;ADC&#41; market, relatively little exposure to virtual (<a href=\"http://esj.com/articles/2011/08/08/physical-virtual-adc.aspx\" target=\"_blank\">software-based</a>) ADCs, <a href=\"https://seekingalpha.com/currents/post/943391\" target=\"_blank\">Amazon Web Services</a>, and mobile. On Friday, UBS estimated F5 <a href=\"https://seekingalpha.com/currents/post/1058751\" target=\"_blank\">lost 500 bps</a> of ADC share on a Y/Y basis in Q1.<div class=\"tiny-share-widget\" data-id=\"1060001\" data-linked=\"13 months after launching coverage with an Overweight and $155 PT, Morgan Stanley downgrades F5...\" data-tweet=\"$FFIV - 13 months after launching coverage with an Overweight and $155 PT, Morgan Stanley downgrades F5 (FFIV -4.4%) to Equal Weight, sending shares below $80. The firm cites valuation, a maturing application delivery controller &amp;#40;ADC&amp;#41; market, re... https://seekingalpha.com/news/1060001?source=tweet\" data-url=\"https://seekingalpha.com/news/1060001\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059951\" data-ts=\"1370266597\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHHBY\" target=\"_blank\">RHHBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059951\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roche&#39;s (OTCQX:RHHBY) Avastin drug failed to extend the survival of patients with a brain cancer...</a></h4><p>Roche's (<a href=\"https://seekingalpha.com/symbol/RHHBY\" title=\"Roche Holding Ltd ADR\">OTCQX:RHHBY</a>) Avastin drug <a href=\"http://www.bloomberg.com/news/2013-06-02/roche-s-avastin-fails-to-add-time-in-brain-cancer-survival-study.html\" target=\"_blank\">failed to extend</a> the survival of patients with a brain cancer called glioblastoma in a trial of 637 subjects. Those who received Avastin and chemotherapy lived a median of 15.7 months vs 16.1 months for those given just chemotherapy. However, Avasatin did help women with an aggressive form of cervical cancer live almost four months longer. Roche's shares <font color=\"red\">-3%</font> in Zurich. (PR <a href=\"http://www.roche.com/media/media_releases/med-cor-2013-06-01.htm\" target=\"_blank\">I</a>, <a href=\"http://www.roche.com/media/media_releases/med-cor-2013-06-02.htm\" target=\"_blank\">II</a>)</p><div class=\"tiny-share-widget\" data-id=\"1059951\" data-linked=\"Roche&#39;s (OTCQX:RHHBY) Avastin drug failed to extend the survival of patients with a brain cancer...\" data-tweet=\"$RHHBY - Roche&#39;s (OTCQX:RHHBY) Avastin drug failed to extend the survival of patients with a brain cancer called glioblastoma in a trial of 637 subjects. Those who received Avastin and chemotherapy lived a median of 15.7 months vs 16.1 months for those ... https://seekingalpha.com/news/1059951?source=tweet\" data-url=\"https://seekingalpha.com/news/1059951\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059891\" data-ts=\"1370265847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFY\" target=\"_blank\">INFY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059891\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infosys (NASDAQ:INFY) +5.2% following news co-founder Narayana Murthy is once more chairman. An...</a></h4>Infosys (NASDAQ:<a href='https://seekingalpha.com/symbol/INFY' title='Infosys Limited, Inc.'>INFY</a>) <font color=\"green\">+5.2%</font> following news co-founder Narayana Murthy is <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/1058991\">once more chairman</a>. An upgrade to Buy from BofA/Merrill can't be hurting either. Murthy, Infosys' CEO from 1981 to 2002 and chairman from 2002 to 2011, played a pivotal role in the IT outsourcing giant's rise. <a target=\"_blank\" href=\"http://blogs.wsj.com/indiarealtime/2013/06/03/can-narayana-murthy-save-infosys/\">JPMorgan sees</a> his comeback strengthening Infosys' push to expand into <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/529751\">high-margin consulting services</a> as demand for basic outsourcing work slumps. <a target=\"_blank\" href=\"http://economictimes.indiatimes.com/opinion/interviews/Narayana-Murthys-return-at-Infosys-is-bizarre-Anil-Singhvi-Ican-Investment-Advisors/articleshow/20405772.cms\">Others</a>, however, think it highlights a leadership vacuum.<div class=\"tiny-share-widget\" data-id=\"1059891\" data-linked=\"Infosys (NASDAQ:INFY) +5.2% following news co-founder Narayana Murthy is once more chairman. An...\" data-tweet=\"$INFY - Infosys (NASDAQ:INFY) +5.2% following news co-founder Narayana Murthy is once more chairman. An upgrade to Buy from BofA/Merrill can&#39;t be hurting either. Murthy, Infosys&#39; CEO from 1981 to 2002 and chairman from 2002 to 2011, played a pivotal rol... https://seekingalpha.com/news/1059891?source=tweet\" data-url=\"https://seekingalpha.com/news/1059891\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059851\" data-ts=\"1370265350\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059851\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Market preview: Stock futures are higher following Friday&#39;s late sell-off and slightly...</a></h4><b>Market preview:</b> <a target=\"_blank\" href=\"http://www.marketwatch.com/story/stock-futures-buck-global-losses-ahead-of-ism-2013-06-03\">Stock futures are higher</a> following Friday's late sell-off and slightly better-than-expected <a target=\"_blank\" href=\"https://seekingalpha.com/currents/search?query=pmi\">PMI data</a>, while Europe reverses early losses after decent manufacturing numbers as well. The S&amp;P Mini is <font color=\"green\">+0.3%</font>. \"It's a heavy week for economic data, and that's going to keep the guessing game of the Fed alive,\" says economist Peter Cardillo. \"It means we can expect more volatility.\" <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/1059061\">Later</a>: ISM Manufacturing Index, Construction Spending<div class=\"tiny-share-widget\" data-id=\"1059851\" data-linked=\"Market preview: Stock futures are higher following Friday&#39;s late sell-off and slightly...\" data-tweet=\"Market preview: Stock futures are higher following Friday&#39;s late sell-off and slightly better-than-expected PMI data, while Europe reverses early losses after decent manufacturing numbers as well. The S&amp;P Mini is +0.3%. &quot;It&#39;s a heavy week for economic d... https://seekingalpha.com/news/1059851?source=tweet\" data-url=\"https://seekingalpha.com/news/1059851\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059841\" data-ts=\"1370265182\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASI\" target=\"_blank\">ASI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059841\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket gainers: ASI +21%. TEAR +11%. PPHM +12%. OSH +9%. CLP +7%. MTL +6%. SODA +5%. INFY...</a></h4><b>Premarket gainers:</b> <a href=\"https://seekingalpha.com/symbol/ASI\" title=\"American Safety Insurance Holdings, Ltd.\">ASI</a> <font color=\"green\">+21%</font>. <a href=\"https://seekingalpha.com/symbol/TEAR\" title=\"TearLab Corporation\">TEAR</a> <font color=\"green\">+11%</font>. PPHM <font color=\"green\">+12%</font>. OSH <font color=\"green\">+9%</font>. <a href=\"https://seekingalpha.com/symbol/CLP\" title=\"Colonial Properties Trust\">CLP</a> <font color=\"green\">+7%</font>. <a href=\"https://seekingalpha.com/symbol/MTL\" title=\"Mechel OAO\">MTL</a> <font color=\"green\">+6%</font>. <a href=\"https://seekingalpha.com/symbol/SODA\" title=\"SodaStream International\">SODA</a> <font color=\"green\">+5%</font>. <a href=\"https://seekingalpha.com/symbol/INFY\" title=\"Infosys Limited, Inc.\">INFY</a> <font color=\"green\">+5%</font>.<br><b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/AFFY\" title=\"Affymax, Inc.\">OTC:AFFY</a> <font color=\"red\">-27%</font>. <a href=\"https://seekingalpha.com/symbol/INFI\" title=\"Infinity Pharmaceuticals, Inc.\">INFI</a> <font color=\"red\">-16%</font>. NBG <font color=\"red\">-13%</font>. SNTA <font color=\"red\">-12%</font>.<div class=\"tiny-share-widget\" data-id=\"1059841\" data-linked=\"Premarket gainers: ASI +21%. TEAR +11%. PPHM +12%. OSH +9%. CLP +7%. MTL +6%. SODA +5%. INFY...\" data-tweet=\"$ASI $ASI $TEAR - Premarket gainers: ASI +21%. TEAR +11%. PPHM +12%. OSH +9%. CLP +7%. MTL +6%. SODA +5%. INFY +5%.Losers: OTC:AFFY -27%. INFI -16%. NBG -13%. SNTA -12%. https://seekingalpha.com/news/1059841?source=tweet\" data-url=\"https://seekingalpha.com/news/1059841\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059781\" data-ts=\"1370264430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SODA\" target=\"_blank\">SODA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059781\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SodaStream (NASDAQ:SODA)&amp;nbsp;gains 5.5% premarket after Barclays ups its price target to $100...</a></h4><p>SodaStream (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SODA\" title=\"SodaStream International\">SODA</a>)<font color=\"green\">gains 5.5%</font> premarket after Barclays <a href=\"https://twitter.com/thenotablecalls/status/341537163114057728\" target=\"_blank\">ups its price target</a> to $100 from $55, saying the product is not a fad and its channel checks indicate 20% top-line growth is conservative. Barclays' bull case for Soda sees the shares as high as $150.</p><div class=\"tiny-share-widget\" data-id=\"1059781\" data-linked=\"SodaStream (NASDAQ:SODA)gains 5.5% premarket after Barclays ups its price target to $100 from...\" data-tweet=\"$SODA - SodaStream (NASDAQ:SODA)gains 5.5% premarket after Barclays ups its price target to $100 from $55, saying the product is not a fad and its channel checks indicate 20% top-line growth is conservative. Barclays&#39; bull case for Soda sees the shares... https://seekingalpha.com/news/1059781?source=tweet\" data-url=\"https://seekingalpha.com/news/1059781\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059751\" data-ts=\"1370264165\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRIS\" target=\"_blank\">CRIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059751\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Data presented at ASCO which shows Curis&#39; (NASDAQ:CRIS) CUDC-427 demonstrated &quot;a favorable...</a></h4><p>Data presented at ASCO which shows Curis' (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CRIS\" title=\"Curis, Inc.\">CRIS</a>) CUDC-427 demonstrated \"a favorable safety profile [and] preliminary signals of clinical activity\" isn't enough to save the shares in early trading, as the stock <font color=\"red\">falls 15.4%</font> premarket.</p><div class=\"tiny-share-widget\" data-id=\"1059751\" data-linked=\"Data presented at ASCO which shows Curis&#39; (NASDAQ:CRIS) CUDC-427 demonstrated &quot;a favorable...\" data-tweet=\"$CRIS - Data presented at ASCO which shows Curis&#39; (NASDAQ:CRIS) CUDC-427 demonstrated &quot;a favorable safety profile [and] preliminary signals of clinical activity&quot; isn&#39;t enough to save the shares in early trading, as the stock falls 15.4% premarket. https://seekingalpha.com/news/1059751?source=tweet\" data-url=\"https://seekingalpha.com/news/1059751\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059741\" data-ts=\"1370263663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFI\" target=\"_blank\">INFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059741\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">It appears JPMorgan was correct when it sounded a cautious tone towards shares of Infinity...</a></h4><p>It appears JPMorgan was correct when it <a href=\"https://seekingalpha.com/currents/post/1030221\" target=\"_blank\">sounded a cautious tone</a> towards shares of Infinity Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/INFI\" title=\"Infinity Pharmaceuticals, Inc.\">INFI</a>) last month ahead of the company's ASCO presentation regarding IPI-145. JPM predicted a \"good showing\" but said it may not be enough given the competition. INFI said Sunday that IPI-145 was \"well tolerated\" in a Phase 1 trial and that the \"rapid onset of clinical activity [was] observed, with a median time to response of 1.9 months.\" Nevertheless, the shares are <font color=\"red\">down 14.6%</font> premarket.</p><div class=\"tiny-share-widget\" data-id=\"1059741\" data-linked=\"It appears JPMorgan was correct when it sounded a cautious tone towards shares of Infinity...\" data-tweet=\"$INFI - It appears JPMorgan was correct when it sounded a cautious tone towards shares of Infinity Pharmaceuticals (NASDAQ:INFI) last month ahead of the company&#39;s ASCO presentation regarding IPI-145. JPM predicted a &quot;good showing&quot; but said it may not be... https://seekingalpha.com/news/1059741?source=tweet\" data-url=\"https://seekingalpha.com/news/1059741\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059711\" data-ts=\"1370263409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDGL\" target=\"_blank\">MDGL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059711\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synta Pharmaceuticals&#39; (SNTA) Ganetespib helped extend the lives of lung-cancer patients to a...</a></h4><p>Synta Pharmaceuticals' (SNTA) Ganetespib helped extend the lives of lung-cancer patients to a median 9.8 months when used with chemotherapy in a Phase II trial vs 7.4 month with subjects that were given just chemo. While shares are <font color=\"green\">+8.4%</font>, The Street's Adam Feuerstein says the trial results were \"<a href=\"http://www.thestreet.com/story/11939068/1/syntas-lung-cancer-drug-struggles-to-remain-relevant.html\" target=\"_blank\">not statistically significant</a> and (were) worse than\" an update from study last September. (PR)</p><div class=\"tiny-share-widget\" data-id=\"1059711\" data-linked=\"Synta Pharmaceuticals&#39; (SNTA) Ganetespib helped extend the lives of lung-cancer patients to a...\" data-tweet=\"$MDGL - Synta Pharmaceuticals&#39; (SNTA) Ganetespib helped extend the lives of lung-cancer patients to a median 9.8 months when used with chemotherapy in a Phase II trial vs 7.4 month with subjects that were given just chemo. While shares are +8.4%, The St... https://seekingalpha.com/news/1059711?source=tweet\" data-url=\"https://seekingalpha.com/news/1059711\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059691\" data-ts=\"1370262767\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDMO\" target=\"_blank\">CDMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059691\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Peregrine Pharmaceuticals (PPHM) soars 8.8% premarket after saying data from Phase 1 and Phase 2...</a></h4><p>Peregrine Pharmaceuticals (PPHM) soars <font color=\"green\">8.8%</font> premarket after saying data from Phase 1 and Phase 2 trials presented at ASCO demonstrate bavituximab's potential for treating HER2-negative metastatic breast cancer and non-resectable Stage IV pancreatic cancer. SA contributor Chris Lacoursiere recently called bavituximab \"the <a href=\"https://seekingalpha.com/article/1458401-peregrine-pharmaceuticals-the-little-biotech-with-the-golden-goose-of-immunotherapy\" target=\"_blank\">golden goose</a> of immunotherapy.\" (PR)</p><div class=\"tiny-share-widget\" data-id=\"1059691\" data-linked=\"Peregrine Pharmaceuticals (PPHM) soars 8.8% premarket after saying data from Phase 1 and Phase 2...\" data-tweet=\"$CDMO - Peregrine Pharmaceuticals (PPHM) soars 8.8% premarket after saying data from Phase 1 and Phase 2 trials presented at ASCO demonstrate bavituximab&#39;s potential for treating HER2-negative metastatic breast cancer and non-resectable Stage IV pancrea... https://seekingalpha.com/news/1059691?source=tweet\" data-url=\"https://seekingalpha.com/news/1059691\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059651\" data-ts=\"1370262081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TUR\" target=\"_blank\">TUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059651\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Turkish stocks (TUR -6.74% premarket) continue to crumble Monday amid anti-government protests....</a></h4><p>Turkish stocks (<a href=\"https://seekingalpha.com/symbol/TUR\" title=\"iShares MSCI Turkey ETF\">TUR</a> <font color=\"red\">-6.74%</font> premarket) continue to crumble Monday amid anti-government protests. The Borsa Instabul is now down <font color=\"red\"><b>8.6%</b></font> on the day and 16% since May 22. Meanwhile, yields on benchmark 2-year Turkish government bonds are up a rather disconcerting 183 basis points over the same period. (Previous: <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/1059201\">I</a>, <a target=\"_blank\" href=\"https://seekingalpha.com/currents/post/1058651\">II</a>)</p><div class=\"tiny-share-widget\" data-id=\"1059651\" data-linked=\"Turkish stocks (TUR -6.74% premarket) continue to crumble Monday amid anti-government protests....\" data-tweet=\"$TUR - Turkish stocks (TUR -6.74% premarket) continue to crumble Monday amid anti-government protests. The Borsa Instabul is now down 8.6% on the day and 16% since May 22. Meanwhile, yields on benchmark 2-year Turkish government bonds are up a rather di... https://seekingalpha.com/news/1059651?source=tweet\" data-url=\"https://seekingalpha.com/news/1059651\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059631\" data-ts=\"1370261954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059631\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Merck (NYSE:MRK)&amp;nbsp;gains 3.9% premarket after an early-stage study on its skin cancer drug...</a></h4><p>Merck (NYSE:<a href=\"https://seekingalpha.com/symbol/MRK\" title=\"Merck &amp; Co Inc.\">MRK</a>)<font color=\"green\">gains 3.9%</font> premarket after an early-stage study on its skin cancer drug labrolizumab shows it <a href=\"http://www.thestreet.com/story/11939006/1/mercks-anti-pd1-melanoma-drugs-shrinks-tumors-in-half-of-patients.html\" target=\"_blank\">shrinking tumors in 38% </a>of advanced melanoma patients. The results were presented yesterday at the ASCO annual meeting. The drug could compete with Bristol-Myers Squibb's novolumab, but BMY is showing no ill effect,<font color=\"green\"> +2.7%</font> premarket.</p><div class=\"tiny-share-widget\" data-id=\"1059631\" data-linked=\"Merck (NYSE:MRK)gains 3.9% premarket after an early-stage study on its skin cancer drug...\" data-tweet=\"$MRK - Merck (NYSE:MRK)gains 3.9% premarket after an early-stage study on its skin cancer drug labrolizumab shows it shrinking tumors in 38% of advanced melanoma patients. The results were presented yesterday at the ASCO annual meeting. The drug could ... https://seekingalpha.com/news/1059631?source=tweet\" data-url=\"https://seekingalpha.com/news/1059631\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059471\" data-ts=\"1370260216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059471\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intel (NASDAQ:INTC)&amp;nbsp;gains 1.3% premarket after getting the Barron&#39;s treatment in a good way...</a></h4><p>Intel (NASDAQ:<a href=\"https://seekingalpha.com/symbol/INTC\" title=\"Intel Corporation\">INTC</a>)<font color=\"green\">gains 1.3%</font> premarket after getting the <a href=\"https://seekingalpha.com/currents/post/1058841\" target=\"_blank\"><em>Barron's</em> treatment</a> in a good way over the weekend. FBR Capital chimes in, <a href=\"https://twitter.com/Briefingcom/status/341519363251249153\" target=\"_blank\">upgrading to Buy</a>.</p><div class=\"tiny-share-widget\" data-id=\"1059471\" data-linked=\"Intel (NASDAQ:INTC)gains 1.3% premarket after getting the Barron&#39;s treatment in a good way over...\" data-tweet=\"$INTC - Intel (NASDAQ:INTC)gains 1.3% premarket after getting the Barron&#39;s treatment in a good way over the weekend. FBR Capital chimes in, upgrading to Buy. https://seekingalpha.com/news/1059471?source=tweet\" data-url=\"https://seekingalpha.com/news/1059471\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059421\" data-ts=\"1370258916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBRL\" target=\"_blank\">CBRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059421\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Cracker Barrel&#39;s (NASDAQ:CBRL) FQ3: For the sixth straight quarter, comps growth is...</a></h4><p>More on Cracker Barrel's (NASDAQ:<a href=\"https://seekingalpha.com/symbol/CBRL\" title=\"Cracker Barrel Old Country Store, Inc.\">CBRL</a>) <a href=\"https://seekingalpha.com/currents/post/1059391\" target=\"_blank\">FQ3</a>: For the sixth straight quarter, comps growth is positive for store traffic (+0.7%), restaurant sales (+3.1%), and retails sales (+5.5%). Operating income margin rises 50 basis points and the <a href=\"https://seekingalpha.com/currents/post/1059401\" target=\"_blank\">dividend is hiked</a> 50% to $0.75/share. Full year outlook: Adjusted EPS of $4.74-4.85 against consensus of $4.79. In an article published Sunday, SA contributor Abba's Aces <a href=\"https://seekingalpha.com/article/1475511-cracker-barrel-fair-value-delightful-dividend\" target=\"_blank\">predicted a 5% pop</a> after earnings \u2014 the stock is more than half way there in premarket trading, <font color=\"green\">up 2.84%</font>. (PR)</p><div class=\"tiny-share-widget\" data-id=\"1059421\" data-linked=\"More on Cracker Barrel&#39;s (NASDAQ:CBRL) FQ3: For the sixth straight quarter, comps growth is...\" data-tweet=\"$CBRL - More on Cracker Barrel&#39;s (NASDAQ:CBRL) FQ3: For the sixth straight quarter, comps growth is positive for store traffic (+0.7%), restaurant sales (+3.1%), and retails sales (+5.5%). Operating income margin rises 50 basis points and the dividend i... https://seekingalpha.com/news/1059421?source=tweet\" data-url=\"https://seekingalpha.com/news/1059421\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059341\" data-ts=\"1370256923\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059341\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Best Buy (NYSE:BBY) is ahead by 3.8% in the premarket following an upgrade to Buy from Hold at...</a></h4><p>Best Buy (NYSE:<a href=\"https://seekingalpha.com/symbol/BBY\" title=\"Best Buy Co.\">BBY</a>) is <font color=\"green\">ahead by 3.8%</font> in the premarket following an <a href=\"https://twitter.com/bored2tears/status/341505579233206272\" target=\"_blank\">upgrade to Buy</a> from Hold at SunTrust, with price target of $35.</p><div class=\"tiny-share-widget\" data-id=\"1059341\" data-linked=\"Best Buy (NYSE:BBY) is ahead by 3.8% in the premarket following an upgrade to Buy from Hold at...\" data-tweet=\"$BBY - Best Buy (NYSE:BBY) is ahead by 3.8% in the premarket following an upgrade to Buy from Hold at SunTrust, with price target of $35. https://seekingalpha.com/news/1059341?source=tweet\" data-url=\"https://seekingalpha.com/news/1059341\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059251\" data-ts=\"1370248491\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNY\" target=\"_blank\">SNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059251\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sanofi (NASDAQ:SNY) will take a $285M charge on its H1 income after saying that it will halt the...</a></h4><p>Sanofi (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SNY\" title=\"Sanofi\">SNY</a>) will take a <a href=\"http://www.bloomberg.com/news/2013-06-03/sanofi-ends-iniparib-research-plans-285-million-charge.html\" target=\"_blank\">$285M charge</a> on its H1 income after saying that it will halt the development of its iniparib drug after it failed in Phase III testing for lung cancer and a Phase II study for ovarian tumors. Sanofi acquired the drug in its $500M acquisition of BiPar Sciences in 2009. Sanofi has also halted the development of its anti-coagulant otamixaban after a poor Phase III trial. Shares are <font color=\"red\">-2.1%</font> in Paris. (PR)</p><div class=\"tiny-share-widget\" data-id=\"1059251\" data-linked=\"Sanofi (NASDAQ:SNY) will take a $285M charge on its H1 income after saying that it will halt the...\" data-tweet=\"$SNY - Sanofi (NASDAQ:SNY) will take a $285M charge on its H1 income after saying that it will halt the development of its iniparib drug after it failed in Phase III testing for lung cancer and a Phase II study for ovarian tumors. Sanofi acquired the dr... https://seekingalpha.com/news/1059251?source=tweet\" data-url=\"https://seekingalpha.com/news/1059251\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059241\" data-ts=\"1370247706\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059241\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">It&#39;s a sea of red on the screen in Europe as stocks follow Japanese shares lower - albeit not as...</a></h4><p>It's a <a href=\"http://www.bloomberg.com/news/2013-06-03/european-stock-futures-drop-indicating-new-four-week-low.html\" target=\"_blank\">sea of red</a> on the screen in Europe as stocks follow <a href=\"https://seekingalpha.com/currents/post/1059161\" target=\"_blank\">Japanese shares</a> lower - albeit not as sharply - despite some rather upbeat eurozone <a href=\"https://seekingalpha.com/currents/search?query=pmi\" target=\"_blank\">PMI data</a>, especially in Spain. \"Fed uncertainty continues to keep traders in a bipolar state,\" says Capital Spreads trader Jonathan Sudaria. EU Stoxx 50 <font color=\"red\">-1.3%</font>, London <font color=\"red\">-1.8%</font>, Paris <font color=\"red\">-1.4%</font>, Frankfurt <font color=\"red\">-1.1%</font>, Madrid <font color=\"red\">-1%</font>, Milan <font color=\"red\">-0.8%</font>.</p><div class=\"tiny-share-widget\" data-id=\"1059241\" data-linked=\"It&#39;s a sea of red on the screen in Europe as stocks follow Japanese shares lower - albeit not as...\" data-tweet=\"It&#39;s a sea of red on the screen in Europe as stocks follow Japanese shares lower - albeit not as sharply - despite some rather upbeat eurozone PMI data, especially in Spain. &quot;Fed uncertainty continues to keep traders in a bipolar state,&quot; says Capital Sp... https://seekingalpha.com/news/1059241?source=tweet\" data-url=\"https://seekingalpha.com/news/1059241\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"1059221\" data-ts=\"1370246471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/1059221\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">German manufacturing PMI climbs to 49.4 in May (flash 49) from 48.1 in April as the sector...</a></h4><p>German manufacturing PMI climbs to 49.4 in May (flash 49) from 48.1 in April as the sector enjoys moderate rises in production and new orders. Input costs drop at the steepest pace in almost two years, although employment continues to fall. \"Germany's manufacturing sector achieved a pronounced change of momentum in May,\" says Markit, with the data \"much less downbeat\" than in April. (PR)</p><div class=\"tiny-share-widget\" data-id=\"1059221\" data-linked=\"German manufacturing PMI climbs to 49.4 in May (flash 49) from 48.1 in April as the sector...\" data-tweet=\"German manufacturing PMI climbs to 49.4 in May (flash 49) from 48.1 in April as the sector enjoys moderate rises in production and new orders. Input costs drop at the steepest pace in almost two years, although employment continues to fall. &quot;Germany&#39;s m... https://seekingalpha.com/news/1059221?source=tweet\" data-url=\"https://seekingalpha.com/news/1059221\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1576818000,"end":1576904399,"str":"Friday, December 20, 2019"},"yesterday":{"start":1576731600,"end":1576817999}}